1.0 LPBI Group’s CALENDAR
2012 to 2020
@@@@@@
@@@@@@
2020 – 1.0 LPBI’s Calendar
12/8/2020
December Global ZOOM Meeting on December 8, 2020
SCIENCE SIDE 11AM EST – 1PM EST
11AM EST – 12:15PM EST
Dr. George Tetz, MD, PhD
Antibiotic resistance
We are fighting antibiotic resistance, by a novel breakthrough diagnostic test named AtbFinder which aims to select effective antibiotics even for drug resistant bacteria for children with respiratory infections when the battle to save life, relies on the selection of effective drugs.
The AtbFinder addresses this with a novel principle for antibiotic selection, which enables it to select effective drugs even against “superbugs,” by selecting antibiotics that target both the “superbugs” and their supporting bacteria, or bacteria helpers, which are required for the growth of “superbugs.”
12:15PM EST – 1PM EST
Dr. Emmanuel Loeb, CEO and Founder, Patho-Logica
Advances of AI in Pathology, Animal Studies, Preclinical Research and Clinical Trials – Exploration of business interface with 2.0 LPBI
BUSINESS SIDE 1PM EST – 4PM EST
1PM EST – 2PM EST – Aviva & Joel
Development and Execution of 2020-2021 Vision
https://pharmaceuticalintelligence.com/vision/
- 2.0 LPBI is not Fee for Service, we are Equity sharing.
- 1.0 LPBI, 2012-2020, defined Equity sharing for all Experts, Authors, Writers (EAWs) as #words per article x Views per article since date of publication across all post published in the Journal.
2.0 LPBI, 2021 – 2025, will pursue four initiatives:
Initiative #1. Wikipedia presence
Initiative #2. New Web Site Design
Two Site Map Proposals for LPBI’s New Web Site
Curators: Gail S. Thornton, PhD(c) and Aviva Lev-Ari, PhD, RN
https://pharmaceuticalintelligence.com/2020/12/02/two-site-map-proposals-for-lpbis-new-web-site/
Initiative #3. Six New Strategies
Initiative #4. New Technology Partnerships for 3.1 to 3.6, below
Initiative #3 Overview description
3.1 NLP, ML, AI on our four Corpuses of Intellectual Property (IP) assets:
3.1.1 6,000 journal articles
3.1.2 16 eBooks in Medicine
3.1.3 100 eProceedings and Tweet Collections of top Biotech and Medical Global Conference we covered in Real Time – See Press Coverage
3.1.4 Content aggregation via Categories of Research combinations
3.2 Monetization of 3.1 of Blockchain Transaction Network, digital store in Healthcare Digital Marketplace
3.3 Podcast Library development
3.4 Conversion of 3.1.1 – 3.1.4 from English Text to English Audio
3.5 Joint venture on Synthetic Biology in Drug Development of Galectins with SBH Sciences, Inc at ABI-LAB
3.6 Conversion of 3.1.1 – 3.1.4 to Foreign Languages: Japanese, Spanish, Russian
2PM EST – 3PM EST – Two candidates for 2.0 LPBI 3.1 and 3.2, above
2PM EST – 2:30PM EST
- Adina Hazan, PhD in Pharmacology, PostDoc level – will join the 2.0 LPBI Medical Text Analysis Team
2:30PM EST – 3PM EST
-
Buddhadeb Pradhan, PhD in CS, PostDoc level – will join the 2.0 LPBI Team and work with Aviva on
- Web Design technical aspects using WordPress Themes with widgets
- Data preparation of IP Asset Classes I, II, III, V for Blockchain deployment
3PM EST – 3:30PM EST – Presentation by Vendor for 3.6 – 16 volumes Translation to Spanish
- Sarah Henter – LPBI Book Translation to Spanish
3:30PM EST – 4:00PM EST – Internal Affairs
- Dr. Williams – 3.1, above
- Joel – IB communication
- Joel – 3.2, above – Alternative quotes from Blockchain vendors, i.e., AWS
- Aviva – Summary
UPDATED on October 25, 2020
November Global ZOOM Meeting on November 10, 2020
Post Meeting: Synopsis ZOOM MEETING 11/10/2020
- Dr. Pearlman had missed his talk
- Dr. Tetz gave an outstanding two talks
- Dr. Tetz – please send us the Slides of your 2nd Talk
- Darryl Glober missed his introduction to the Board
- Aditya Bahl send us comments on 1.0 LPBI Brochure
- Aditya Bahl agreed to connect with Dr. Tetz directly for further Business relations
- George Gamota edified the Team on the importance of comparables for valuation of assets
- George Gamota, please assist us with an Elevator Pitch
- Amber Harley, BurstIQ – will send a quote
- Wendy Charles, BurstIQ – will describe strategic partnership program
- Dr. Nir used the wrong Zoom Link and enter Zoom spending time in a Waiting Room – SORRY !!!!!!!!
- Prof. Feldman – did not have an opportunity to talk, we had a conversation on ML at 5PM EST today
- Dr. Williams expressed the frontier of innovations @LPBI since 2012: Nitric Oxide e-Book, 3D BioPrinting, NLP, ML, AI on our content, Blockchain
- Joel Shertok disbelieves the new trend in healthcare toward Blockchain, he is aware of the ecosystem of that emerging market
- Dr. Saha need to connect Dr. Bahl to explore collaboration
- Irina enjoyed Dr. Tetz talks
- Gail concurred the workflow for approaching the IB and posted schedule for Newsletters.
- Offer made few very good points
- Inbar Ofer was introduced to the Team as INTERN with a plate full of tasks
AGENDA
- 11AM EST – 12PM EST
Dr. George Tetz, MD, PhD
Bacteriophages as a novel human pathogens. Phagobiome – a novel diagnostic tool
A lot of my research is focused on the studying the role of bacteriophages as human pathogens. Our core was the first to show that bacteriophages may be implicated in a variety of human diseases and can be considered to be previously unexplored cause of Parkinson’s diseases, type 1 diabetes and other multifaceted pathologies. We have already evaluated at least 4 crucial pathogenic mechanisms of how bacteriophages trigger human diseases, including those associated with protein misfolding. This gave us an opportunity for the first time to use phages as a therapeutic targets to prevent and treat neurodegenerative and autoimmune diseases, bringing therapy to a next transformative step.
The use of bacteriophages as a novel diagnostic tool is under development
https://www.nature.com/articles/s41598-017-07278-6
https://www.nature.com/articles/s41598-018-29173-4
https://www.nature.com/articles/s41598-019-46087-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6027513/
https://www.mdpi.com/2076-2607/6/2/54
- 12PM EST – 1PM EST – No Lecture
Dr. Justin D. Pearlman, MD, PhD – 50% NLRP3 and 50% own Dissertation research on this topic
Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis
- 1PM EST – 2PM EST – Business Side
Elevator Pitch and PowerPoint Slide Deck
- 2PM – 3PM – BurstIQ
- 3PM – 3:30PM EST Internal Deliberation on timing to approach IB
UPDATED on September 22, 2020
Agenda for October 20, 2020 11AM EST – Zoom Global LPBI Meeting
11AM EST Dr. George Tetz, MD, PhD, Cholesterol crystals and the enzyme Deoxyribonuclease I (DNase1) roles in coronary atherosclerosis and apoptosis
12PM EST Dr. Justin D. Perlman, MD, PhD, FACC, Cholesterol crystals use complement to increase NLRP3 signaling pathways in coronary and carotid atherosclerosis
UPDATED on September 12, 2020
September 15, 2020 – Global Zoom Meeting, 11AM EST – 3PM EST
- 11- Noon, Dr. George Tez, MD, PhD, Lecture #2: RE: Lecture #1 (Repeat and Continued) Gene Editing and Therapeutics for Pancreatic Cancer
- Noon – 1PM EST, Dr. George Tez, MD, PhD, Lecture #3: Potential Applications of AAV-based vector encoding human Deoxyribonuclease I enzyme for treatment of Fibrosis
- Fibrosis in the Liver as a result of NASH – of interest to Dr. Raphael Nir
- Fibrosis in the Myocardium as a result of Ischemia – of interest to Dr. Pearlman and to Aviva
- Cardiovascular scarring due to Stent implantation, atherosclerosis and arterial stiffness – of interest to Dr. Pearlman and to Aviva
- Endogenous treatment with PCSK9 inhibitors for Hyperlipidemia – of interest to Dr. Pearlman
1,2,3,4 above could be Therapeutic CONCEPTS of CLS Therapeutics PLATFORM for other indications than oncology and may have potential for a NEW venture that will license PATENT protected IP from CLS Therapeutics
1PM EST – 1:40PM EST Clustering of Country-Based Data in COVID-19 Infections by Coronavirus outbreak features – First wave, Data up to date 28/5/2020 | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Authors: Akad Doha, Markman Ofer and Lefkort Jared
1:40PM EST – 2:20PM EST Opportunity Mapping of the E-Health Sector prior to COVID19 Outbreak | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
Authors: Akad Doha, Markman Ofer and Lefkort Jared
2:20PM EST – 2:30PM EST Joel & Aviva Venture Valuation – Financial Document ONE Summary PAGE by Joel to cover
- 1.0 LPBI, 4/2012 – 12/2020
- 2.0 LPBI, 1/2021 – 12/2025
- Combined 1.0 & 2.0
2:30PM EST – 4PM EST LPBI Group’s Team meets with BurstIQ to discuss EXPLORATION of BUSINESS and Partnership
UPDATED on August 18, 2020
Global Zoom Monthly meeting on 8/18/2020
AGENDA for TUESDAY, August 18, 2020 11AM EST to 3PM EST
[Zoom 2:30PM – will be 3PM]
11AM EST – noon EST – Monthly Zoom PRESENTAION TO LPBI EXTERNAL BUSINESS RELATIONS
by an Entrepreneur in Therapeutics
- EXTERNAL SCIENTIFIC RELATIONS – Dr. George Tetz, MD, PhD, CEO CLS Therapeutics, will present Stem Cell Therapeutics for Pancreatic Cancer. He is seeking PARTNERSHIPS with big Pharma and FUNDING
45 minutes Presentation – George Tetz, MD, PhD, CEO, CLS Therapeutics – Stem Cell Therapeutics for Pancreatic Cancer
15 minutes Discussion
ALL LPBI Group’s EXTERNAL BUSINESS RELATIONS
- Dr. Raphael Nir, Potential Investor
- George Gamota, Jr., ESQ – ex-Wall Street – Funding sources
- Aditya Bahl, MBA – ex–J&J, Novartis – Partnerships with Big Pharma – Please consider Roche, Basel for George Tetz, MD, PhD, CEO, CLS Therapeutics
- John St. Cyr, MD, PhD – Business and Medicine Fusion
- John Sviokla, PhD, MBA, HBS – Strategy Maestro
- Philip Guarino, MBA, Wharton – Le Marketer Tour de Force
- Please ALL lean-in to advise George Tetz, MD, PhD, CEO, CLS Therapeutics
- Feel free to contact him directly after the meeting
ALL LPBI Group’s EXTERNAL SCIENTIFIC RELATIONS
- Prof. Ajay Gupta
- Prof. Sol Yedgar
- Dr. Yigal Blum
- Dr. Albert El-Roeiy
- Dr. Rapahel Nir
- Please ALL lean-in to advise George Tetz, MD, PhD, CEO, CLS Therapeutics
- Feel free to contact him directly after the meeting
NOON to 2PM EST – LPBI presents to ALL LPBI Group’s EXTERNAL BUSINESS RELATIONS
- Noon to 1PM EST Prediction Modeling for Article Views on PharmaceuticalIntelligence.com, 2021 – 2025 by Prof. H. Lev-Ari, Fellow IEEE – Markov Renewal Process – SEE 1st ATTACHMENT
- 1PM – 1:30PM Dr. Joel Shertok, Assumptions based Scenarios – Financial Aspects of Venture Valuation:
1.0 LPBI & 2.0 LPBI – Two distinct business entities in SUCCESSION: 2012 – 2020 begets 2021 – 2025 –
SEE 2nd ATTACHMENT
- 1:30PM – 2PM Aviva will present: GRAND TOTALS – Financial VALUATION OF IP ASSETS
[DATA DERIVED FROM REAL VIEWS records of 1.8 MILLIONS data points and +6,000 articles published in a time series x views per each – stratified sampling and number articles published by month in NINE years – Markov Renewal Process Model – BIG DATA in the hands of top Professor of EE – Signal Processing day by day, 1971 – Present]
- 2.0 LPBI Predictions for ALL TNS #1,2,3,4,5,6 Revenue Potential Prediction about $50 Million <<<<<<<< ——-DATA DRIVEN Model
- 1.0 LPBI – Ten IP Asset Classes about $50 Million <<<<<<<< ——-DATA DRIVEN Model
- Combining Two distinct business entities: 1.0 PLUS 2.0 ~~~ $100 MIllion Valuation !!!!!!!!
- These numbers go to our Investment Banker in NY – these two attachment Draft —>> FINAL after Labor Day 2020.
- AVIVA will be set Free for TNS #1 with ALL NEW INTERNS Team
- 2PM – 3PM – LPBI INTERNAL Meeting
Dynamic NEWS:
- AVIVA – >> STAY TUNE for additional announcements RE: 2.0 LPBI Leadership
- 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP) started on 8/17/2020 at 5PM EST https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/
- Proof of Concept for Client in UT – ON ITS WAY – no outsourcing!!!! – all new IP and Composition of Methods —>> stay HOME!!
- AVIVA – >> 2020 VISION Development of TNS #1: Phase 1, Phase 2, Phase 3 – SW Vendor Choices for NLP https://pharmaceuticalintelligence.com/vision/
On 8/15/2020, All Time
1,805,940
Number of Journal articles
5,900
UPDATED on July 21, 2020
NEXT Monthly Meeting on August 18, 2020 11AM EST – 4PM EST
Final Agenda for July 21, 2020
11AM EST to 4PM EST
Monthly Zoom Meeting with
External Scientific Relations and with
External Business Relations
July 21, 2020: 11AM EST to 1PM EST
Presentations on Drug Repurposing MOA and Database for COVID-19
11AM EST to Noon – A one hour discussion by two presenters of the MOA of their drug – repurposed for COVID-19
- 20 minutes: Prof. Saul Yedgar – see one pager attachment
- 20 minutes Prof. Ajay Gupta
- 20 minutes DISCUSSION
- No need for Power Point Presentations – One pager from Dr. Saul Yedgar shared in attachment
- The AUDIENCE had attended BOTH presentations
- Prof. Saul had reviewed Prof. Gupta’s PowerPoint and Prof. Gupta was sent the Summary of Prof. Yedgar
Noon – 12:30PM – Dr. Williams presents Castleman COVID-19 DRUG REPOSITORY of Repurposed Drug in Clinical Trials @UPENN
- Please focus on POSITIVE effects
The Castleman Disease Research Network publishes Phase 1 Results of Drug Repurposing Database for COVID-19
12:30PM – 12:45PM – Aviva will present three NEW Initiatives @ LPBI
I. Debut on Wikipedia with three ENTRIES
- Three NEW Entries on Wikipedia: (a) 1.0 LPBI (b) 2.0 LPBI (3) Founder of 1.0 LPBI & 2.0 LPBI
II. The LAUNCH of 2.0 LPBI – 2021 & Beyond – A New Website on WordPress.com
III. 2.0 LPBI – 2021 & Beyond – The New Strategies (TNS #1, TNS #2, TNS #3, TNS #4)
- TNS #1: Text Analysis with NLP, ML, AI
- TNS #2: Blockchain infrastructure – The PLATFORM to sell Journal Articles, e-Books, e–Proceedings & Tweet Collections
- TNS #3: Audio-Video Podcasts Library
- TNS #4: Research concept for the Joint Venture between LPBI and ABI-Lab
12:45PM – 1PM – Dr. Raphael Nir – Presents a Research concept for the Joint Venture between LPBI and ABI-Lab
July 21, 2020 – 1PM EST to 4PM EST
THREE Presentations on 2.0 LPBI STRATEGY
1PM – 2PM – Philip G. – Candidate for a C-Level spot at LPBI Group
- 20 minutes: Philip G. – Introduction of an Executive Profile with relevant experience to 2.0 LPBI – 2021 & Beyond
- 20 minutes – 1.0 LPBI Team Introduction by Expertise and Role at 1.0 LPBI
- 20 minutes – Free Exchange
2PM – 3PM – TDP, Palo Alto, CA
https://www.decisionplatform.io/
- Jim Beddows, President and his Executives, Exploration of a Partnership in Text Analysis using NLP, ML, AI for LPBI’s Genomics and Cancer books for a potential client in the Health Care Insurance sector
3PM – 4PM – BurstIQ, Denver, CO
- Dr. Wendy Charles, CSO, Blockchain and LPBI Group – Exploring Opportunities for platform use and the BurstIQ’s Research Foundry
UPDATED on June 19, 2020
-
LPBI’s Reorganization ANNOUNCEMENT at Zoom Meeting on
June 23, 2020, 2PM EST – 5PM EST
-
LPBI’s Next Monthly Zoom Meeting during the Pandemic on
July 21, 2020 11AM EST – 2PM EST
UPDATED on June 9, 2020
HEADS UP for June 16, 2020 11AM EST ZOOM Meeting: UPDATES in Calendar – Check everyday
THIS IS A VERY IMPORTANT MEETING for the future of LPBI
– ONLY All ACTIVE FIT members need to attend this meeting at its FULL length.
Place the whole day on your Calendar
– This in a FOUR hours meeting – ACTIVE FIT TEAM MEMBERS MUST ATTEND, see your name, below.
– Confirm that you are ready with your presentation
Part One
1. External Scientific Relations:
Development of Novel Therapeutics for COVID-19
• Prof. Saul Yedgar, HUJI – 45 min
• Prof. Ajay Gupta, MD – 45 min
• Yigal Blum, PhD – ACC – 5 min
Discussion – 20 min
1.1 What LPBI can do for and with the presenters
1.2 What the Business External Relations can do for the presenters
Part Two
2. External Business Relations: GG, AB
2.1 LPBI Marketing Communication Material is READY
Presentations by:
• Rick and Gail – LPBI’s Slide Deck Library – How the deck powers your 11 slides??
• Jason S. Zielonka, MD, AFACC – LPBI Slide Deck for Big Pharma – 45 min
• Joel – LPBI Brochure, 20pps document
• Aviva – Prospectus, 220pps
2.2 Assignment of Contact roles for presentation to Intermediaries and Prospects
Aviva to obtain confirmations from:
• Rick & Joel – IB in NYC to be contacted by Phone ☎️ after 4th of July. After she received HARD COPY material from Aviva
• George – FIN in US
• AB – Pharma, FIN, Publishing – Europe
Part Three
LPBI – Monthly Zoom INTERNAL Meeting for ACTIVE FIT members
and Daniel and Nitin
3. Presentations by:
Aviva presents Knowledge Portals System (KPS) – One Page with nested pages per ACTIVE FIT members for documenting PAST contributions and activities on behalf of LPBI from July 2020 till the Exit
Option 1: A Name is in the Organization chart for Exit purposes, July 5, 2020
- Set of Requirements presented and e-Sign off sheet e-mailed – Signatory material to enter Hard copy documentation
Option 2: Name on Our TEAM – Name is Not In Organization chart for Exit purposes, July 5, 2020
2.1 Past contributors voluntarily joining 2/19/2019 Transition Phase:
- Dr. Larry H. Bernstein – In Active status
- Dr. Adam Sonnenberg – In Active status
- Dr. Justin D. Pearlman – In Active status
- Dr. Dror Nir – In Active status
- Dr. Ritu Saxena – In Active status
- Alex Crystal – In Active status
2.2 External Relations & Advisors [Name is in the Organization Chart by Initials]
Presentations by
• Daniel Menzin – NEW results on LPBI Twitter handles: @pharma_BI, @AVIVA1950 – Analytics on Followers and their Number of Followers
• Dr. Williams and Ofer (Noam Ordan) and Daniel
– AI, NLP, ML for Text Analysis of LPBI’s four e-Books: Scientists and CS/AI Collaboration on What to look for AND setting guiding rules for algorithm searching in
– Cancer: vol 1&2
– Genomics: vol 1&2
UPDATED on 5/28/2020
Sharing with you the May 11, 2020 event attended by 11,000 Global Physicians and Health Care Professionals
By Aviva
e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
VIEW ALL VIDEOS by Mass General Brigham Hospitals
https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg
By Aviva
Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET
UPDATED on 5/28/2020
Our Next ALL ACTIVE LPBI TEAM MEMBERS
ZOOM Meeting will be on June 16, 2020 11AM EST
AGENDA – 6/16/2020
Part I: Therapeutics for COVID-19
- Prof. Saul Yedgar – Holder of US Patents on Rhinitis, anti-inflatation and other indications – 40 minutes
- Dr. Ajay Gupta, MD – Rhinitis drug approved in Japan – FDA Application for Approval of Repurpusing to COVID-19 in the US – 40 minutes
- Discussion – 20 minutes
Part II: Dr. Jason S. Zielonka, MD, AFACC – The Role LPBI can play for Big Pharma R&D and IP development Needs – 45 minutes
- Collaborations with External Relations – Inclusion of Affiliates in Approaching Big Pharma
- All External Relations that wish representation of their IP to Big Pharma by LPBI need to get Guest Author Status and Affiliate Status with LPBI Group
- Contact directly Aviva IF you vote YES at least on ONE on the following options:
- Wish to become Guest Author on the Journal – Lead: Aviva
- Wish to become External Relations – entailes you to an invitation to Monthly meetings and access to all iCloud LPBI Group Resources – Lead: Aviva
- Wish to be represented by LPBI Group for Regulation and/or Funding purposes – Leads: Dr. Jaosn and George
- Wish to be teamed up with an LPBI Scientist or an LPBI Business executive to discuss JOINT IP or Market development – Leads: Dr. Williams and Rich Mandahl
Part III: LPBI’s Exit Options – 35 minutes
- Joel T. Shertok, PhD – LPBI’s Brochure (20pps) and LPBI’s Prospectus (220pps) – 5 minutes
- Aviva Lev-Ari, PhD, RN — Scouting and Prospecting Strategy: Pros and Cons of each Option – 5 minutes
- 12 Economic Segments – Division of Labor among FIT Member CAPTURED on Knowledge PORTALS System (KPS) – 5 minutes
Each ACTIVE FIT Member needs to DECLARE the Industry he/she wishes to focus on and using KPS to promote LPBI’s Products and PLAY A VITAL ROLE IN PROSPECTING FOR AN ACQUIRER – aiming to get personally 10% of the Proceeds of the Exit if responsible for finalizing the Exit transaction.
- Discussion with Mr. GG and Mr. AB: What role they wish to play for the Exit [Internal or External] – 20 minutes
Please reply if you wish to ATTEND 6/16/2020 Meeting – if YES THEN in what capacity
UPDATED on 5/27/2020
From: Rick Mandahl <rmandahl@gmail.com>
Date: Wednesday, May 27, 2020 at 10:48 AM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Cc: “Stephen Williams, PhD” <sjwilliamspa@comcast.net>, Marcus W Feldman <mfeldman@stanford.edu>, “Dr. Jason Zielonka, MD” <Jasonz.mit@gmail.com>, “Irina Robu, PhD” <irina.stefania@gmail.com>, “Dr. Sudipta Saha” <sudiptasaha1977@gmail.com>, Ofer Markman <oferm2020@gmail.com>, George Gamota <gngamotajr.us@verizon.net>, Gail Thornton <gailsthornton@yahoo.com>, Joel Shertok <jshertok@yahoo.com>
Subject: Re: THANK YOU NOTE
To LPBI members on this note, special kudos to Dr Williams and Dr Zielonka for your tight, succinct, compelling presentations. I do not know if George was present at that time but believe he would approve. Also very powerful comments by Aviva describing the “reach” of LPBI content compared to most journals. Excellent meeting. Thank you Aviva for setting it up. Rick
On 5/27/2020 Aviva wrote in response to RIck:
On June 16, 2020, 11AM EST – LPBI Zoom Meeting with External Relations:
- Dr. Jason S. Zielonka will have 45 minutes to presents: Aviva and Jason are working on this Slide Deck for Pharma
- Pharma’s Need in R&D and IP
- Positioning of LPBI for Partnership and/or Part of the Enterprise by LPBI Product Lines
- George will attend June 16
- Wr. Williams will have 5 minutes to Present IP Asset Classes: I, II, III, VI
- Presentations by Prof. Yedgar and Dr. Ajay Gupta – have COVID-19 Therapeutical solutions in the very same space – anti-inflammatory
- Mr. BAHL will attend [confirmation pending]
- Aviva and JOEL – will Present 20pps Summary with a 220 [JOEL – figure out with WordPress definition for hits on Home Page / Archive – for LPBI this definition is of $20Million WORTH OF VIEWS]
- TO OUR SLIDE LIBRARY of of 56 SLIDES (attachment 2) we are adding 22 Slides from the first attachment, here
I am glad that Rick, Joel and Ofer attended [Nitin Shah was there]
TEN OUTCOMES of the Meeting:
- Dr. Larry had attended !!!!!!!!! – He likes Zoom.
- Gail is INTERVIEWING Dr. Larry for a PODCAST
- We have expended our Expert Sphere of Affiliates: Dr. Orna, Dr. Ajay Gupta, Dr. Blum
- Aviva is explore with Dr. Albert EL ROEIY – his potential serving as Co-EDITOR for Volume #17 – he is OBGYN and the book is on Reproduction
- Yigal Blum and Jason will be talking
- Aviva is talking with Dr. Nir
- Following 6/16 – Presentations by Prof. Yedgar and Dr. Gupta – George will be asked to handle both Therapeutics for his sphere of influence
- Orna enjoyed and she is sharing that with her Partner Avishai Levy – an ex-Wietzman Institute known figure in Biotech in Israel
- Per Rick’s Comment – we may get Scientific Papers of the presenters for our Journal
- Aviva presented
-
State of Science
RNA from the SARS-CoV-2 virus taking over the cells it infects: Virulence – Pathogen’s ability to infect a Resistant Host: The Imbalance between Controlling Virus Replication versus Activation of the Adaptive Immune Response
Curator: Aviva Lev-Ari, PhD, RN – I added colors and bold face
https://pharmaceuticalintelligence.com/2020/05/23/rna-from-the-sars-cov-2-virus-taking-over-the-cells-it-infects-virulence-pathogens-ability-to-infect-a-resistant-host-the-imbalance-between-controlling-virus-replication-versus-activation-of-the/
-
-
LPBI Position
-
T cells found in COVID-19 patients ‘bode well’ for long-term immunity | Science | AAAS
https://www.sciencemag.org/news/2020/05/t-cells-found-covid-19-patients-bode-well-long-term-immunity
Clinical Trial for the Use of Nitric Oxide to Treat Severe COVID-19 Infection
https://pharmaceuticalintelligence.com/2020/04/14/clinical-trial-for-the-use-of-nitric-oxide-to-treat-severe-covid-19/
TEN Great outcomes
Thank you all
Aviva Lev-Ari, PhD, RN
UPDATED on 5/26/2020
AGENDA for May 26, 2020 Zoom Meeting 11AM EST
- Drug Discovery for COVID-19 Presentations by External Relations to LPBI Group
External Relations Presenters:
- Dr. Raphael Nir, PhD, CSO, SBH, Sciences, Inc. – Drug Concept to mitigate Cytokine Storm in COVID-19
- Dr. Ajay Gupta, MD, Professor & Entrepreneur – Rhinitis drug approved in Japan – REPURPOSED for COVID-19 and Application for FDA Approval
- Dr. Yigal Blum, PhD, ex-SRI Int’l VP and Entrepreneur – AMORPHOUS CALCIUM CARBONATE (ACC) TREATMENT FOR COVID-19
- Dr. Orna Harel, PhD, Managing Partner, Agbiopro – https://www.linkedin.com/in/orna-harel/
- Presentation on Agbiopro, and
- Representation for Prof. Saul Yedgar on the concept and state of preclinical efforts for COVID-19 drug development
- Prof. Yedgar will present in person to the LPBI Team on June 16, 2020 LPBI Group – Team of Scientists Presenters:
[ALL Business-side is advised to attend]
- Dr. Jason S. Zielonka, MD, AFACC – The Potential Role of LPBI Group’s Portfolio of Intellectual Property Assets for Big Pharma and Biotech firms
- Prof. Marcus W. Feldman, PhD, Stanford University – LPBI Group, Member of the Board, What did LPBI Group accomplished to date
- Prof. Stephen J. Williams, PhD, Temple University – LPBI Group, Member of the Board
- Overview of Asset Class I,II,III and VI
- Consideration Criteria
- Aviva Lev-Ari, PhD, RN – The Potential of REVIVAL of Drug DIscovery Initiative and Explorations of Joint Ventures with Biotech companies – An Interim Phase toward POST Coronavirus Pandemic Exit
DISCUSSION – Where and What is the INTERFACE between what our External Relations attempt to accomplish and the Capabilities of LPBI Group’s Team
- Dr. Raphael Nir, PhD, CSO, SBH, Sceinces, Inc. – Drug Concept to mitigate Cytokine Storm in COVID-19
- Dr. Ajay Gupta, MD, Professor & Entrepreneur – Rhinitis drug approved in Japan – REPURPOSED for COVID-19 and Application for FDA Approval
- Dr. Yigal Blum, PhD, ex-SRI Int’l VP and Entrepreneur – AMORPHOUS CALCIUM CARBONATE (ACC) TREATMENT FOR COVID-19
- Dr. Orna Harel, PhD, Managing Partner, Agbiopro – https://www.linkedin.com/in/orna-harel/
UPDATED on 5/16/2020
Three Zoom SESSIONS – 2Q 2020: May and June
May 19, 2020 11AM EST – ALL FIT MEMBERS – Global Bimonthly – Impact of the Pandemic and Progress report by all FIT Members
- Presentation of Power Point SLIDE DECK to George
- Launch Artificial Intelligence in Genomics & Cancer Portal
- Launch Knowledge Portals System (KPS) – Why and How to develop content
- Nitin will present a Conceptual Strategic Model for Goal Attainment
- ALL FIT members will comment on the above initiatives
May 26, 11AM EST – ZOOM MEETING on Four Novel Rx for COVID-19 – In attendance: EXTERNAL RELATIONS PRESENTING to LPBI Group Therapeutic Concepts – Drug Development – Regulatory & Funding
Presenters of Novel Rx for COVID-19
- Prof. AG, MD
- Prof. SY, PhD
- CEO, RNir, PhD
- VP, YBlum, PhD
June 16, 2020 11AM EST – ALL FIT MEMBERS – LPBI’s several plans for one EXIT
- Presentation 200pps and 20pps PAGER and SLIDE DECK to Mr. BAHL
- Mr. BAHL in attendance
UPDATED on 5/7/2020
5/19/2020 – The Rationale for Launching Knowledge PORTALS Systems (KPS)
KPS is LPBI Group’s HR in the iCLOUD –>>>> IP Asset Class V is LPBI’s TEAM OF EXPERTS
- What did each FIT Member publish in LPBI’s e-Books?
- What did each FIT Member publish in the Journal?
- What on COVID-19?
- What recent was published in 2020?
The Knowledge Portals System have in one place all the contributions to LPBI on ONE PAGE under FIT Member’s Name and the Expertise by the FIT Member’s name
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
- IF an External relations need a QUICK look at FIT members – Only Knowledge Portals System will have ONE page per Member with every angle in it. Picture and Bio – SAME format for each FIT member
- OUR Team – consists of ALL Contributors to the Website, 4/2012 – 5/2020 Not easy to find a Member if you do not know what was the role a member is classified in. Our Team has ALL contributors to the Journal vs a focus on the FIT members
- On KPS – each FIT Member will have several nested PAGES:
- List of articles in books as part of all articles in the Journal will show LEVEL of contribution
- List of posts on COVID-19 – will show LEVEL of authenticity
- RECENT posts in Domain of Expertise – will show LEVEL of currency
4. Since the the launch of the Coronavirus Portal – ALL FIT members have EDITOR privileges and they can write to PAGES vs AUTHOR privileges allowing one’s to write only on own posts.
5. The Coronavirus Portal REMAINS the same and ALL will publish to it to all pages. On Each Personal Portal’s Page on the COronaVirus Pandemic – each FIT member will cite the ArticleID in the Journal (Post TiTLE & URL) and the dates of their UPDATES to the Portal Pages
6. The Knowledge Portals System is for exposition of EXPERTISE @ LPBI per FIT Member – All what you will post since the launch 5/19/2020 on your domain of expertise will be on your own Portal. as a Reference on the RECENT posts in Domain of Expertise PAGE – will show LEVEL of currency
ADVANTAGES of Knowledge Portals System (KPS):
- External relations that need to research the Team of Experts will go from Portal to Portal, from FIT member to FIT member
- Page 1 – Picture and Bio and Link to CV
- Nested Page 2 – ALL articles published in the Journal ADDED (*) for Articles in e-Books a Template of all books Title and URL which will be placed on each FIT member Portal of the Science Side & Science & Business
- Nested Page 3 – What FIT Member Published on the Coronavirus Portal – already there, just to carried over is the LIST of POST published on COVID-19
- Nested Page 4 – RECENT publishing in domains of Expertise – EXAMPLE: Irina Robu, PhD – 3D BioPrinting, Tissue Engineering, Biomaterials, Nanotechnology & Drug Delivery
Responsibilities @LPBI for ALL Science-Side:
(1) Curator initiated new content creation
(2) Updates to own published articles in the Journal
(3) Commissions by the Editor-in-Chief
(4) Client facing engagement with External relations
(5) Advice for the Founder
- External relations will go to KPS and find the features of IP Asset IV: Platforms, as well as see the virtue of the Platform we use
|
Asset Class VI |
Team of Experts See IP Asset Class IV: Platforms it is used for knowledge organization of IP Asset Class VI: Team of Experts
https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/ |
BIOs Final Improvement Team (FIT)
|
UPDATED on 5/4/2020
The Zoom SESSIONS – 2Q 2020: May and June
May 19, 2020 11AM EST – ALL FIT MEMBERS – Global Bimonthly – Impact of the Pandemic and Progress report by all FIT Members
- Presentation of Power Point SLIDE DECK and 20pps PAGER to George
- George in Skype attendance – representing LPBI to Private Equity community per his contacts on Wall Street
May 26, 11AM EST – ZOOM MEETING on THREE Novel Rx for COVID-19 – EXTERNAL RELATIONS PRESENTING to LPBI Group Therapeutic Concepts – Drug Development – Regulatory & Funding
Presenters of Novel Rx for COVID-19
- Prof. AG, MD
- Prof. SY, PhD
- CEO, RN, PhD
June 16, 2020 11AM EST – ALL FIT MEMBERS – LPBI’s several plans for one EXIT
- Presentation 200pps and 20pps PAGER and SLIDE DECK to Mr. BAHL
- Mr. BAHL in attendance
THANK YOU ALL
UPDATED on 4/27/2020
- Global Skype TUESDAY 4/28 at 11AM EST – Aviva will call you on Skype – – THIS IS A MUST ATTEND SKYPE SESSION – THREE hours session
- ATTEND AND BE an ACTIVE participants when you are called to voice your opinion
- Allow the flow of presentation VAST number of NEW ideas and content we plan to cover
THREE NEW SKYPE SESSIONS – 2Q 2020: April, May, June
We will have a MONTHLY meeting during the Economic shutdown of the Economy when EXITS, M&A, IPO and 401K are in DORMANT mode
April 28, 2020 11AM EST – ALL FIT MEMBERS in Attendance
A. Presentation by Dr. Williams – he is covering in REAL TIME the Virtual AACancer Research on 4/27 – 4/29/2020
Highlights & Details
- Twitter Analytics and LinkedIn Views &
- Impact of LPBI’s Coronavirus PORTAL
B. Presentations by Aviva
Highlights & Details
- Tutorial of Coronavirus PORTAL and
- PROPOSAL for Design of NEW PORTALS
- The Powerpoint SLIDE DECK in attachment – all to review before the Meeting
- Introduction and Launch of the Concept of PORTALS managed by FIT MEMBERS
- Progress status on LPBI Documentation preparedness & readiness: PPT, 20pps PAGER, 220pps Business Plan
- Aviva will Introduce Mr. Nitin Shah https://www.linkedin.com/in/nitin-shah-64bb701/ – Nitin is a Microbiologist with a Finance MBA and +30 years of Business Development experience in small and medium PHARMA – he is a candidate for our Business Side. Upon completion of attendance of 2Q 2020 three meetings – Nitin will submit to LPBI a MOU on WHAT his contributions will be, the process he will apply to achieve his goals and what interface will be created to most effectively interact with our Business Side in place:
- RIck – Key relations: IB, SelectHealth, Crain Communications
- Joel & Jason: Reuters’ Clarivate Analytics: IP Division – Pharma
- Joel – Bot-based prospecting system for LPBI Exit
- Jason – Focus on R&D department in Big Pharma to promote LPBI Asset classes: I, II, III, IV & X
- Ofer – Biotech in Israel, Switzerland and other European countries
- Gail – Marketing communication & e-Voices Audio/Video Podcasting Library in formation – Asset Class X
Aviva will offer a TUTORIAL on How to Post AND How to Publish on a PAGE in a PORTAL – a MUST MASTER SKILL by all ACTIVE FIT members during the Economic shutdown of the Economy – we are PUBLISHERS, we do not have labs to run, we do not manage Clinical Trials, we do not perform primary research – we are CURATORS and PUBLISHERS
Every FIT ACTIVE MEMBER will demonstrate contributions to LPBI if
- They will curate content in our Healthcare related domains – NEW POSTS
- They will publish to content in Portals that they will individually manage on topic of their interest – New Initiative to be launched by Aviva on 4/28/2020
- They will continue to work on LPBI’s Coronavirus Portal – The ALL hands on deck first PORTAL launched on 3/14/2020
The other SKYPE SESSIONS – 2Q 2020: May and June
May 19, 2020 11AM EST – ALL FIT MEMBERS – Global Bimonthly – Impact of the Pandemic and Progress report by all FIT Members
- Presentation of Power Point SLIDE DECK and 20pps PAGER to George
- George in Skype attendance – representing LPBI to Private Equity community per his contacts on Wall Street
June 16, 2020 11AM EST – ALL FIT MEMBERS – LPBI’s several plans for one EXIT
- Presentation 200pps and 20pps PAGER and SLIDE DECK to Mr. BAHL
- Mr. BAHL in attendance
THANK YOU ALL – SEE on 4/28/2020 at 11AM EST
UPDATED on 4/23/2020 – THIS IS RECOMMENDED to FIT Members – Following
LPBI NEW SKYPE SESSIONS:
April 28, 2020 11AM EST – ALL FIT MEMBERS – Tutorial of Coronavirus PORTAL and PROPOSAL for Design of NEW PORTALS
- Presentations by Aviva
- Presentation by Dr. Williams – Twitter Analytics and linkedIn Views & Impact of LPBI’s Coronavirus PORTAL
|
|||||||||||||
|
Shaping the narrative: effective science communication in the COVID-19 era
With COVID-19 headlines rapidly changing, it can be hard for many to separate fact from fiction, science from sensationalism.
Many scientists, regardless of their field of study, are being called upon to help families, friends and the community at large understand the evolving pandemic. You’re invited to join the American Society for Biochemistry and Molecular Biology for a webinar on effective science communication in the COVID-19 era.
|
|||||||||||||
|
|
UPDATED on 4/21/2020
THREE NEW SKYPE SESSIONS:
April 28, 2020 11AM EST – ALL FIT MEMBERS – Tutorial of Coronavirus PORTAL and PROPOSAL for Design of NEW PORTALS
- Presentations by Aviva
- Presentation by Dr. Williams – Twitter Analytics and linkedIn Views & Impact of LPBI’s Coronavirus PORTAL
May 19, 2020 11AM EST – ALL FIT MEMBERS – Global Bimonthly – Impact of the Pandemic and Progress report by all FIT Members
- Presentation of Power Point SLIDE DECK and 20pps PAGER to George
June 16, 2020 11AM EST – ALL FIT MEMBERS – LPBI plans for an EXIT
- Presentation 200pps and 20pps PAGER and SLIDE DECK to Mr. BAHL
Attention ALL LPBI’s FIT ACTIVE Members
- GLOBAL ECONOMIC RECESSION is been precipitated by SARS-CoV-2 Pandemic
The Impact Of The Coronavirus Crisis On Mergers And Acquisitions
LPBI REACTIONS:
- LPBI plans for an EXIT had been postponed by 60 days, to be revisited again on June 16, 2020 ALL FIT MEMBERS GLOBAL SKYPE, 11AM EST
- LPBI must continue activities in ALL our IP Asset Classes to be ready for the Exit in POST SARS-CoV-2
- LBPI Products in LPBI’s List of Assets in 2020 include the following THAT require DEMONSTRATION of TEAM CONTRIBUTIONS:
Asset Class I: Journal articles – All FIT Members must POST articles till the Exit and beyond
Asset Class II: e-Books in Medicine – eTOCs of Volume #17 in attachment – Work–in-Progress
Asset Class III: e- Proceedings of Biotech and Medical Conferences & Tweet Collections from these events – VIRTUAL Coverage by ALL FIT members auditing WEBINARS – CREATE a Post with the WEBINAR LINK and ADD summary of your OWN impressions as LPBI’s KOL
Asset Class X: e-Voices Audio Podcast – a Library in formation – GAIL’s activity will continue
Asset Class IV: Platforms – Coronavirus Portal covering 7 topics & Breaking News Corner – ALL FIT Members have assigned Pages on the Portal
WE WILL PULL THROUGH
UPDATED on 3/25/2020
John Hopkins University
Medical School, Coronavirus Resource Center
Meeting Registration Approved
Topic
The Coronavirus Crisis: Responses in China, Italy, and the United States
Description
In the past month, the coronavirus has caused a public health crisis across the world. Governments have scrambled to contain and mitigate the crisis, with very different results. Why have some governments taken aggressive action, while others have adopted a more cautious response? How effective have these responses been? Join this webinar to hear Johns Hopkins SAIS faculty experts discuss responses to the coronavirus in China, Italy, and the United States.
Speakers:
Carla Freeman, Associate Research Professor of China Studies
Erik Jones, Professor of European Studies and International Political Economy
Andrew Mertha, George and Sadie Hyman Professor of China Studies
Meeting ID:
To Join the Meeting
Join from a PC, Mac, iPad, iPhone or Android device:
Please click this URL to join. https://jh.zoom.us/w/991697294?tk=BlR4-WTuet5jEmd8U-L2m6QYG-rvBikkjImr93RCggs.DQEAAAAAOxwZjhZHcm1ndkhqU1FMdUNUeFVvbmZKMUJBAA
UPDATED on 3/25/2020
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||||||||||||||||||||
UPDATED on 3/21/2020
https://mcusercontent.com/5c25136c60d4dfc4d3bb36eee/images/e8f806b7-600c-4b0b-a4e5-8897e5eb1b7d.jpeg
UPDATED ON 3/21/2020
THIS IS THE LIST OF FIT MEMBERS FORTHCOMING SKYPE MEETINGS following
- 3/14 Launch of the Coronavirus Portal and
- 3/17 Skype meeting with External Relations
On Monday 3/23/2020
9AM EST – Aviva & Joel work on Business Plan – MUST be ready 4/19/2020, following that day Aviva starts active prospecting for the Exit
10:30AM EST – Aviva e-mailed you about Webinar from Tel Aviv University Experts on Coronavirus
- Recommended to you
NOON EST – TUTORIAL ON PUBLISHING Guidelines for LPBI’s Coronavirus Portal
https://pharmaceuticalintelligence.com/coronavirus-portal/
- MUST BE ATTENDED by ACTIVE FIT members – it is not Recommended to you (=Optional)
ALL ACTIVE MEMBER OF FIT ARE to be
ACTIVE contributors to 1,2,3, below
1. the Journal
1.1 You contribute articles on 12 declared categories of research out of 700 you submitted prior for been granted access to the Platform
1.2 contribute articles on Coronavirus a POST in the Journal REQUIRES checking off from the following Categories:
- Joel & Gail – GO BACK to your MARCH 2020 POSTS and add categories
– Population Health Management
—— Coronavirus, SARS
Antibody Responses Predict Antigen Exposure, BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics, COVID-19, Immunodiagnostics, Immunology, Innovation in Immunology Diagnostics, MHC Repertoires for Antigen Prediction, Population Health Management, Population Health Management, Genetics & Pharmaceutical, Viral diseases, Virology – Vector-borne DIsease | Tagged BioIT: BioInformatics, Biological Engineering, Biological Networks, Biomarkers & Medical Diagnostics, Cancer Informatics, Clinical & Translational, clinical genomics, Commercialization, COVID-19, Gene Regulation and Evolution, Genetics & Pharmaceutical, Immunotherapy, Innovation in Immunology Diagnostics, Innovations, Intellectual property, Investment in Technological Breakthrough, NGS, Pharmaceutical R&D Informatics, Population Health Management, Proteomics, SARS-CoV, SARS-CoV-2, Universal Immune Cell Therapies (uICT), Virus Infective Acute Respiratory Syndrome: SARS-CoV | Tagged COVID-19
1.3 Carrying over 1.2 above to the Coronavirus Portal
https://pharmaceuticalintelligence.com/coronavirus-portal/
1.3.3 On a page that your article is relevant to
Seven Selected Topics &
Lead Curator for Contact for GUEST AUTHORS:
2. PUBLISH CONTENT on the Coronavirus Portal
2.1 you publish DIRECTLY to any PAGE at the Coronavirus Portal [PAGES has no Categories – they form the architecture of the website]
2.1.1 one page direct publishing content
or
2.1.2 the Title, Author Name, degree, URL of a POST you posted in the Journal
3. CONNECTING ALL POSTS and ALL PAGES UPDATED to SOCIAL MEDIA
3.1 Twitter.com [The ICON on your Post in the Journal is connected to LPBI’s Official Twitter Handle @pharma_BI
- GO THERE and CHECK WHO follows LPBI !!!!!!!!!!!!
- GO TO @AVIVA1950
- CHECK WHO follows Aviva !!!!!!!!!!!! – She Tweets ONLY LPBI-related
3.2 Facebook – connect to PUBLIC, LPBI Page, Your Friends
3.3 LinkedIn
3.3.1 everyone + @pharma_BI
3.3.2 ALL your CONNECTIONS
3.3.3 SOME of your Groups
TUE – March 24, 11AM EST
Skype for ALL BUSINESS-side addressing comments by External Relations: George G.
to be attended by ALL Business-side:
- Rick
- Gail
- Joel
- Jason
- Ofer
- Aviva
THU – March 26, 2PM EST – WEBINAR Responding to COVID-19
On Fri, Mar 20, 2020 at 6:22 PM Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:
WEBINAR: Responding to COVID-19 – Rapid Development and Launch Strategies for Diagnostics, Vaccines, and Therapeutics in a Global Pandemic
Thursday, March 26, 2020 1:00 p.m. – 2:30 p.m. CDT
COVID-19 Webinar for Life Sciences Businesses: Join Us to Explore Rapid Development and Launch Strategies for Diagnostics, Vaccines, and Therapeutics
- Recommended to you – e-mail Sent to you
@@@@@
UPDATED on 3/9/2020
TWO MEETINGS in MARCH 2020
We are on Skype on Friday 3/13/2020 at 11AM EST – 1PM EST
- That meeting is about a Chief Scientific Officer Dr. JZ, MD candidate presenting himself to the Board and the Team.
- The Board and the Team will ask him questions
- We will explain him the business goals and new focus in 2020
- We may have one external relations person joining Dr. RL. He can introduce us to two Global Publishers.
- We may have second external relations person joining Mr. AA, CEO K. He can introduce us to potential acquirer
These two external relations MAY join us on 3/13 at for the meeting at 11AM EST OR AFTER the meeting at 1PM EST
We are on Skype on Tuesday 3/17/2020 11AM EST – 2PM EST – External Relations: Dr. Mak, Mr. Bahl, Mr. George G. – 2 are ex-Big Pharma and one was/is in the Financial sector
We have on Tuesday 3/17/2020 2PM EST – 4PM – Internal Team Meeting FIT members
- 11AM EST – noon is a presenter from Madrid, Spain, He presents his Diagnostics to these three External relations
- noon to 1PM – Aviva is presenting the Business Plan to these three External relations for their comments.
- Draft Document #3 for the IB prepared by Joel and Aviva
- 1PM -1:15PM The summary numbers for each of the Nine IP asset classes are detailed in Excel spread sheets for each asset class – Summary & Explanations will be presented by Joel Shertok.
- 1:20PM EST – 2PM External relations will provide comments and discussion
- 2PM EST – 4PM – Internal Team Meeting ALL FIT Members: Each member present PROGRESS made since 1/14/2020 on tasks they are working on.
Updated on 2/9/2020
1. We updated the Testimonials on LPBI Group on 2/9/2020
https://pharmaceuticalintelligence.com/praising-lpbi/
2. Aviva and Joel are working on Table Numerical Updates [TNU] for inclusion in Document #3 for the IB
- Ready for Presentation to External relations on 3/17
- To be sent to IB as Final on 4/19/2020
Weekly Skype session will take place on
2/11 at 3PM
2/12 9AM – noon
2/17 at 9AM
2/24 at 9AM 10:45AM
3/2 at 9AM
3/13 at 9AM
3. Aviva is seeking One volunteer to work on an Update 2/27/2019 to 3/17/2020 of ALL our Page downloads on Amazon.com for 16 e-Books — work involved tallying numbers inside the Kernel of Amazon.com
- Training to be provided by Prof. HLA
4. Aviva is seeking One volunteer to work on an Update 2/27/2019 to 3/17/2020 of ALL our Twitter Analytics for
- @AVIVA1950
- @pharma_BI
5. We are seeking advice on Partnerships for development of AI applications using NLP and ML algorithms for Text analysis on our CONTENT – English text:
- 5700 Journal articles,
- 16 e-Books,
- 70 Biotech & Medical e-Proceedings]
- Forthcoming Skype with Gregory and of Gil Press – ALL Send me your availability
- Forthcoming Skype with Prof. Noam Ordan – ALL Send me your availability
Please Read:
https://link.wired.com/view/5be9cb353f92a40469de971ebji89.izb/7c1fcd6d
6. We will get safely BACK to SelectHealth regarding AI on LPBI Content for Payors needs
[RICK] <<—AI Partnership [OFER]
7. We will get a new to Intermountain Health Care
about LPBI without AI [RICK]
with SelectHealth + AI [RICK] + [OFER]
8. We will get safely to March 17, 2020 to meet on Skype our External relations to further our EXIT PLAN using their Networks
[AVIVA]
9. We will get safely to April 19, 2020 the submission of Document #3 to IB in NYC
[AVIVA]
10. Follow up with the IB in NYC, ONE WEEK after 4/19/2020
[RICK]
11. Joel will report on 3/17/2020 on his
- Communications with Jeff Roy, President, Clarivate Analytics Intellectual Property Group, part of Calrivate Analytics, Parent company is Reuters
- Efforts to identify an Operations Management Scientist for LPBI Group to overlap with Aviva
- Progress on Bot-Based Prospecting System for LPBI Group using Aviva’s 1st and 2nd Level connections on LinkedIn
[JOEL]
12. List of 84 Followers of BioCentury.docx that we follow on Twitter by
- @AVIVA1950 and by
- @pharma_BI
e-mail sent on 2/4/2020 – We will Follow by Twitter Messages to each or to several groupings same message using Twitter handle of each
13. Letters to Dean of Medical Schools was e-mailed on 2/4/2020 to all FIT members to follow with an e-mail to their assigned State
- Please all complete e-mailing by 3/17 – to report Task completion and follow up by calls
14. List of Names of ResearchGate members recommending our Books – See Update on 1/31/2020
https://pharmaceuticalintelligence.com/praising-lpbi/
List of Names was sent to FIT members on 2/9/2020 for use by Gail to
- Create Podcasts or obtain Testimonials
- Include in March Newsletter
15. ALL SCIENTISTS: Article Updates continues as each was assigned. If not sure e-mail me.
Updated on 1/26/2020
1/27/2020 Skype 60 minutes Presentation of Boaz to LPBI
on what he and his team did with CANCER Volume 2 received from Irina on 1/22-1/23
It will take place on Monday, 1/27/2020
– 10:45AM MST – Rick
– 12:45PM EST – Aviva, Dr. Williams
– 19:45PM EST – Israel: Boaz, Ofer
Updated on 1/26/2020
AGENDA for January 28 Meeting with Dr. Roy G., CMO SelectHealth
- Boaz will attend 1/28 with SelectHealth’s CMO, Dr. Roy G.
- Rick arranged WebEx of SelectHealth with LPBI Group is on 1/28/2020 at
2PM MST
4PM EST
11PM Israel
- Attendance by LPBI to include: Boaz, Rick, Aviva, Dr. Williams, Ofer
PRESENTATIONS
- Dr. Roy G. will present an overview of SelectHealth and Intermountain Health Care and AI Projects in HealthIT
- BOAZ will present AI in Pharma & Thought on How to use LPBI Corpuses with AI
- Dr. Williams will Present our VAST intellectual property (IP) portfolio includes three asset classes:
A. LPBI Scientific Journal:
https://lnkd.in/eEw5q7N
1.7Million eReaders, 5700 scientific articles, 690 categories of research
B. BioMed e-Series:
https://lnkd.in/ekWGNqA
16 Volumes in Medicine
C. e-Proceedings:
https://lnkd.in/dc2qGAK
Corpus of 70 events covered in real time
D. Platform, systems and composition of methods in addition to above three universes of deep content.
E. Journal’s ART GALLERY – collection of biological images courtesy of Google Images and Shutterfly placed in original collages and inside articles for used ORIGINAL to EAWs on LPBI Group’s Team
F. The Team
DISCUSSION – Boaz, Dr. Williams, Ofer, Rick, Aviva & Dr. Roy G.
NEXT STEPS
1/26/2020
+12 Global Skype meetings took place already to get to 1/28/2020, below.
• Ofer approached Aviva about a partnership with PomiCell in early 11/2019
• 11/13 – 11/14/2019 – Aviva is at HMS, covering the 15th Annual
Personalized Medicine Conference in real time. Doing so since 2014.
• Next to Aviva on 3rd row at 7:50AM on 11/13/2019 arrived to sit Dr. Roy
G., a panelist for 10:30AM Panel, he introduces himself to me as
oncologist, CMO and President of SelectHealth, an Oncology Practice in
Salt Lake City.
Aviva tells him that
• LPBI Group was approached for a partnership by an Israeli start up AI
in Pharma
• We have 2 books on Genomics and 2 books on Cancer
• Application of NLP-AI on the text of these four Volume may yield
insight relevant to Healthcare Insurers
Dr. Roy G. said,
• I am on the Board of Intermountain Health Care, Salt Lake City, UT, the
Parent of SelectHealth, we also are in SLC.
• I am interested to explore more what you have and what the Israeli AI
in Pharma start up has
• this is my e-mail, please follow up
Aviva said:
• Our Business Development, Rick Mandahl is based in SLC, he will connect
with your office to follow up.
Since that exchange on 11/13/2019:
• Aviva gave Rick the e-mail of Dr. Roy G.
• Aviva and Ofer scheduled several Skype sessions with Boaz, CEO of
PomiCell which in early November was interested in a Partnership with
LPBI Group
• Aviva mentioned to Ofer and Boaz that SelectHealth in Oncology and
Intermountain Health Care – are interested in applications of AI to their
own HealthCare issues:
– SelectHealth: Provider of Oncology treatments
– Intermountain: HMO and HealthCare Insurer
• Aviva conditioned the partnership with PomiCell on Boaz and his Team to
apply their AI-NLP-ML-NeuralNet on TEXT of LPBI Groups IP three asset
classes:
– Articles,
– Books,
– eProceedings
EVENTS:
1. Friday, January 17 at 5PM – Office of Dr. Roy G. returns the call of
Rick Mandahl placed in mid December 2019.
2. The suggested WebEx of SelectHealth with LPBI Group is on 1/28/2020 at
2PM MST
4PM EST
11PM Israel
3. Rick sent on Saturday, 1/18 e-mail to Aviva that 1/28 will be
Introduction of LPBI to SelectHealth/Intermountain HC
4. Aviva explains that Dr. Roy G. is interested in AI in Oncology and in
AI for roles of HC Insurer, Intermountain.
Therefore, 1/28 should be:
Boaz presenting applications of AI on LPBI Text. I had in mind +1200
articles on Cancer in the Journal
5. On 1/21/2020 – our Internal LPBI meeting focused on a discussion
regarding the TEXT in MS Word needed by Boaz to use his AI.
• Dr. Williams suggested to use the MS Word format of Cancer Volume 1 & 2
• Aviva asks Irina to fetch from DropBox the 3400 pages, Volume 2 and send it to Boaz. She does that on Wed 1/22
or Thu 1/23
• Boaz calls a meeting with Aviva for Thu 1/23 – took place at 10PM Israel
• Boaz and Offer and Aviva meet on Friday 1/24
Aviva e-mails all:
1/27/2020 Skype 60 minutes Presentation of Boaz to LPBI on what he and his
team did with CANCER Volume 2 received from Irina on 1/22-1/23
It will take place on Monday, 1/27/2020
– 10:45AM MST – Rick
– 12:45PM EST – Aviva, Dr. Williams
– 19:45PM EST – Israel: Boaz, Ofer
1/28/2020 WebEx with
Dr. Roy G. and Rick at 2PM MST
and
Boaz and Ofer – 11PM Israel
Aviva, Dr. Williams – 4PM EST
On 3/17/2020 11AM EST – Bi-monthly with external relations: Dr. Mak, Mr. Bahl, Dr. Raphael Nir
The decision on Scenarios:
• 1 – we are what we are
• 2 – 1, above plus AI-NPL-ML-NeuralNets
• 3 – only outcome of 2, above
On 4/19/2020 – we send Document #3 to the Investment Banker in NYC.
1/26/2020
We have 3/17/2020 major Global Skype with three advisors on three Scenarios on HOW TO POSITION LPBI Group for Exit:
Scenario 1:
We are what we are:
1.1 Journal – 5700 scientific articles:
1400 are LHB’s
1000 are All Scientists combined
3355 are ALA’s
1.2 BioMed e-Series – average length of book: 2400 pages, Sixteen Volumes in five specialties of Medicine
– Cardiovascular – 6 volumes
– Genomics – 2 volumes
– Cancer – 2 volumes
– Immune System & Infectious Diseases – 3 volumes
– Precision Medicine – 4 volumes
1.3 Seventy eProceedings and Collections of Tweets made in Real time at 70 most prominent Biotech & Medicine Global Conferences, 2013-2020
1.4 Platform, composition of methods, workflow, templates to produce 1.1, 1.2, 1,3, above – The tools 🛠 🧰 to create curations for Journals and Books
1.5 A collection of 5,000 graphics of biological images used in 1.4
1.6 The Team
Scenario #2:
Scenario #1 plus NLP-AI derived insights
Scenario #3:
Only insights derived from the application of NLP-AI on our three CORPUSES
1.1 apply on every article,
N = 5700
1.2 apply on every eBook,
N = 16
1.3 apply on every eProceedings N = 70 and on every collection of Tweets N = 30
What is the BEST POSITIONING FOR EXIT:
Scenario #1: we are what we are
Scenario #2: Application of NLP-AI on Scenario #1
Scenario #3: Only the outcome of Scenario #2 targeted to problem solving in 12 economic segment of the economy
That decision needs to be reflected in Document #3 to be sent to IB in NYC on 4/19/2020
Updated on 1/20/2020 @6PM
WHAT ARE THE NEEDS OF LPBI GROUP IN 2020
AGENDA for 1/21/2020 11AM EST
Because we have a meeting on 1/28 with SelectHealth, we asked PomiCell’s CEO to prepare a presentation on his AI algorithms on our Cancer related articles. He will arrive to the Meeting to present.
- We will discuss what he will present in the 2nd half of the meeting on 1/28/2020 with SelectHealth
Task 1: Finalize 2020 BUZ_PLN aka Document #3 for the IB in NYC
- Document Owner: Aviva
- Contact Manager: Rick
- Contact Owner: Aviva
- Input to the Document: Dr. Williams and Gail
This is a Quarterly engagement
To accomplish finalization of the document we need the following OR WE NEED TO DECLARE EACH AS NEEDED BUT NOT TO BE INCLUDED IN THIS ROUND
IF IN RED – MEANS must be in the document
- We need 12 write ups one per Economic Segment on HOW OUR IP CAN BECOME A MONEY MAKER in each of these segment if applied in the process of the specific value creation by a player in each of the 12 segments under the assumption that all incumbents in a segment will apply our IP in the same fashion — (not necessarily true) but this simplification is acceptable as a working hypothesis.
- Examples:
Big Pharma: Roche and Pfizer – both will use our articles for the same purpose: R&D, drug repurposing and clinical trial design
Publishers: All incumbents will sell each article for $30 multiple times
- We need an INTERN to assign the #Views per article From EXCEL file create by Alex Crystal for 5700 articles: Views per article to all article in each Volume
- We need to recalculate Twitter Intangibles for @pharma_BI and for @AVIVA1950 for Followers Followers from 4/2019 to 12/31/2019
- We need Dr. Williams to create a Comparison table for Our Journal vs GenomeWeb – Behaviors of e-Readers
- We need to Complete IP_VAL_CALC tool to derive the factors in valuation of our IP
- We need to place a range for an ASKING PRICE of
- The Journal [N = +5700] based on sell each article for $30 multiple times
- The Books [N = 16] based on book asking price times assumptions of Market penetrations
- The e-Proceedings [N = 70]
SOURCES in need of work to finalize for this round of 2020 BUZ_PLN
- Financial Valuation of Three Health Care Intellectual Property (IP) Content Asset Classes
- Global Market Penetration Forecast for each Volume in the 16 Volume BioMed e-Series
- Potential Use of LPBI IP as Value Price Driver by Potential Acquirer: Assumptions per Asset Class
- Gail and Dr. Williams to select Tables from Section #13 for inclusion in 2020 BUZ_PLN
- For the 2020 BUZ_PLN – we need for EVERY MEMBER NAME ON OUR FIT
- Each must submit an UPDATED CV to Aviva
- 1/2 Page Bio
Task 2: Going DIRECT for finding an M&A partner – We do need to prepare infrastructure for that eventuality that our IB does not takes us on.
This is a Quarterly engagement that all Business Side members are involved in USING their NETWORKS of contacts
2.1 Joel’s Bot based prospecting system for LPBI Group will start with Aviva’s +7,000 contacts on LinkedIn – Starting Project on January 2020
Task 3: Internet Presence – LPBI Group’s 2020 Needs:
3.1 Our Website needs a Portal for the 12 Economic Segments
Potential assignment: Aviva + XX
3.2 LPBI LinkedIn Page needs re-CONSTRUCTION – all the content is already on our website
Potential assignment: Aviva + XX
3.3 LPBI FaceBook Page needs re-CONSTRUCTION – all the content is already on our website
Potential assignment: Aviva + XX
3.4 LPBI Group’s LinkedIn Group needs TLC and Community building and content posting from our website
Potential assignment: Aviva + XX
3.5 Aviva’s articles on LinkedIn needs to be Shared once a month within Social Media: Facebook, LinkedIn, Twitter – BECAUSE THESE ARTICLES ARE about LPBI Group’s IP – go and look at them – EACH FIT MEMBER MUST SHARE THEM on social media
https://www.linkedin.com/in/avivalevari/detail/recent-activity/posts/
3.6 Gail will develop our Newsletter and our Podcast – Audio pipeline and embed SoundCloud on our Journal posts under these two categories
3.7 Gail will define new objectives she wants to accomplish for LPBI Group as her time will allows her.
Task 4: Relations Management
4.1 1Q 2020 – Rick
- IB in NYC
- CEO Crain Communications, Inc.
- CMO Select Health & Intermountain Health Care System – Meeting on 1/28/2020
- 2Q 2020 Rick will bring to LPBI Group’s new prospects for the Exit
4.2 1Q 2020 – Ofer
- LPBI Group and PomiCell relations: Exploration, Definition, NDA, J-V?? Clients joint engagement
- Biotech Ecosystem in Israel – Introductions: Aviva and Biotech CEOs
- DayOne Basel – https://www.dayone.swiss/dayone.html – The Swiss Innovation Hub for Precision Medicine – Introductions of LPBI Group
- 2Q 2020 Ofer will bring to LPBI Group’s new prospects for the Exit
4.3 1Q 2020 – Dr. Mak and Mr. Bahl
- On 3/17/2020 our 2nd Bimonthly Global Skype meeting we will discuss the involvement of
Dr. Mak (ex-Pfizer R&D and Ventures) with LPBI Group
- On 3/17/2020 our 2nd Bimonthly Global Skype meeting we will discuss the involvement of
Mr. Bahl (ex-J&J, ex-Novartis) with LPBI Group
Task 5: The entire SCIENCE TEAM continues the following activities in the victorious aura of COMPLETION of LPBI Group’s BioMed e-Series N=16 Volumes:
5.1 Dr. Williams needs to fetch from the Journal 5 best articles for each of our Chapters on Reproductive and Endocrine Genomics for a potential Volume #17 with 4.2 Dr. Saha as Author and Dr. Williams and Aviva as Editors. I am trying to see if such a Topic is more sexy for selling eBooks. I thank Dr. Saha and Dr. Williams for their contributions to this POTENTIAL volume, aka #17. SEE ATTACHMENT HERE.
5.3 Dr. Kaul if will come back as ACTIVE member of FIT – will needs to post one curation per week as condition for maintaining ACTIVE status
5.4 Drs. Irina, Saha, Pearlman and Aviva will need to post regularly in the Journal
5.5 Dr. Williams needs to continually update his articles and 2016 articles of Dr. Larry
5.6 Dr. Saha needs to update own articles
5.7 Dr. Irina needs to update own articles and 7/2015 – 12/2015 of Dr. Larry’s articles.
Task 6: ALL FIT MEMBERS are involved in Promotion of BioMed e-Series to Medical Schools in the US and Globally, as follows: WE HAVE THE LETTER WE WISH YOU TO USE READY FOR YOU
– Monthly engagement
| BioMed e-Series introduction to Medical Schools | ||
| Science
Team |
Monthly milestones two schools send e-mail to Specialty Faculty Members on ONE series | |
| Dr. Irina Robu | Series E
in Canada |
|
| Dr. Sudipta Saha | Series D
in India |
|
| ________
Dr. Justin Pearlman |
_________
Series A MA, ME |
|
| Dr. Stephen J. Williams | Series B & C
PA & MD |
|
| Prof. Feldman | All Series
OR AZ |
|
| Aviva | All Series
MA |
|
| Business-side
Team |
||
| Gail | Series E
NJ |
|
| Ofer
and XXX |
Series E
ISRAEL Series A ISRAEL Series B and C France Series D Switzerland Series E Quebec, Canada |
|
| Rick | Series B, Genomics
UT |
|
| Aviva | Series A and B
SPAIN and Japan |
|
Joel Series, A,B,C,D,E in State of DE
EACH ATTENDEE will present at the meeting:
- Please prepare WHAT ARE YOUR GOALS for 1Q 2020
- Please present them to the Team
AVAILABLE FOR TRANSFER OF OWNERSHIP AND POSITIONING FOR AN ACQUISITION
ARE THE FOLLOWING ECONOMIC ASSETS:
The Team of Experts: SJW, AK, IR, JDP, ALA
and
Business Side: GT, RM, OM, ??JS??
Our Portfolio of IP has five asset classes
We target the PROSPECTING effort following our – WHERE are the needs for our IP Assets are in greatest NEED, study our:
Opportunities Map in the Acquisition Arena
Our VAST intellectual property (IP) portfolio includes three asset classes:
A. LPBI Scientific Journal:
1.7Million eReaders, 5700 scientific articles, 690 categories of research
B. BioMed e-Series:
16 Volumes in Medicine
C. e-Proceedings:
Corpus of 70 events covered in real time
D. Platform, systems and composition of methods in addition to above three universes of deep content.
E. Journal’s ART GALLERY – collection of biological images courtesy of Google Images and Shutterfly placed in original collages and inside articles for used ORIGINAL to EAWs on LPBI Group’s Team
@@@@@@@@
For January 14, 2020, 11AM EST our Bi-monthly THREE hours Skype, I have planned the following:
UPDATED on 1/14/2020
UPDATED ORDER OF PRESENTATIONS
- Aviva make introductions of people
- PomiCell’s CEO, Israel
- Aditya Bahl, Germany, On LPBI
- Joanna, Israel, On LPBI
- Joel, Delaware, US, On LPBI
- Ofer Markman, Israel, On PomiCell and LPBI
- Ribograma, Spain
- Discussion on External relations presentations: 2,3,7 [PomiCell, Mr. Bahl, Ribograma]
- Discussion on Internal presentations: 4,5,6 [Joanna, Joel, Ofer]
UPDATED ON 1/13/2020
On 1/14 we will have EXTERNAL relations that we will bounce concepts on them and LPBI will be open minded to get their feedback.
- Dr. Mak – ex–Pfizer, CT
From: “Dr. Makarand Jawadekar (ref. Gayatri Sarkar)” <mjawadekar@yahoo.com>
Date: Monday, January 13, 2020 at 4:20 PM
To: “Aditya Bahl (ref. Mak)” <aditya@raslss.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Re: We are expecting to see BOTH of you tomorrow on our Global Skype
Dear Aviva,
I am on a Flight tomorrow and therefore, will NOT be able to attend the SKYPE call. I will however do it in March.
Best regards,
Mak
- CONFIRMED – Aditya Bahl – ex– Novartis & ex- J&J, Frankfurt, Germany
- CONFIRMED – Ofer Markman, Israel, Biotech Hub in Haifa
- PENDING- AA, PwC, Israel ??
CONFIRMED – PomiCell, CEO will present a NLP algorithms applied to our Journal and Books
- We would like the EXTERNAL relations to advice us on this potential partnership
CONFIRMED – Ribograma, CEO will present a Diagnostics concept in Oncology
- We would like the EXTERNAL relations to advice them on potential partnership they are seeking – LPBI will not be involved with Ribograma
- Ribograma’s CEO can give as an entry to the Dean of Medical School in Madrid in exchange to LPBI giving him exposure to our EXTERNAL relations
Aditya Bahl will present a conceptual piece on EXIT STRATEGY for LPBI
- EXTERNAL relations and the entire LPBI Team will have a discussion on his presentation
For feedback by EXTERNAL relations:
- Joel will have two short presentations:
- He will present the Headers of the document we are preparing as a Business Plan
- He will present the concept of Global prospecting using bots
- Aviva will ask EXTERNAL relations
- to review the Document for their own prospecting in their own networks for Acquirer candidates for LPBI
- How to integration our document with Aditya Bahl’s Exit conceptualization as he will present a conceptual piece on EXIT STRATEGY for LPBI
- Joanna’s will present her approach for the French speaking market – We need an Entry point to France, Quebec and Switzerland and the European Union
- LPBI is not bound to the US market. We need to use the talent that is interested in working with LPBI per the highest point of their expertise
- I believe in regional geography and Marketing Communication need be regional vs Global
- Aviva would ask EXTERNAL relations perspective on Joanna’s approach – she worked for Sanofi in France in marketing communication and knows Pharma in Europe
- Gail will ask Joanna questions about her conceptual PowerPoint
- Aviva would ask the scientists to comment as well on her conceptual plan
On 1/21 11AM EST we will have an Internal meeting of all FIT Members – for 2020 LPBI Task Assignments
- Gail will present her Plan to take feedback from the Scientists and create an operations plan to execute
- Rick will present his progress on three contacts he is pursuing:
- IB
- Crain’s CEO
- SelectHealth CMO / Intermountain
Aviva will present the 12 economic segments on the Opportunity Map and the type of write up we need for
- The document we are preparing for the IB and our need to create per each of the 12 economic segments a plan HOW THEY CAN USE OUR IP for their business
- Will suggest HOW we shall divide the 12 economic segment among FIT members to work on a Project to create a conceptual piece on applications of our IP in each of the segments PER THE SEGMENTS that they will choose to be assigned to
- Each FIT member will work on Three segment with other FIT members and each small team will work with Aviva on this task
- We will produce 4-5 Pages per industry – HOW LPBI IP can be used internally at each segment
- PRODUCTS of 4, above will be used by Joel for the Business Plan and by Aviva to create the PORTAL for our to be Redesigned Web site
BREAKDOWN OF POTENTIAL ACQUIRERS: Twelve Economic Segments
|
Classification |
Potential Strategies |
LPBI Business Lines |
||||||
@@@@@
A. External relations will attend and present on January 14, 2020, 11AM EST
For January 14, 2020, 11AM EST our Bi-monthly THREE hours Skype, I have planned the following:
AGENDA UPDATES on Calendar on our Website
https://pharmaceuticalintelligence.com/calendar/
Aviva will present 5 Executives, External relations to LPBI Group attending the meeting:
- Boaz B., CEO, PomiCell.com – Presenter at the meeting – Seeker of Partnership with LPBI Group and his start up
- Dr. M. J., ex-Pfizer, Consultant to Aviva on Big Pharma US – Exit assistance
- Mr. A.B., ex-Novartis, ex-J&J, Consultant to Aviva on Big Pharma Europe – Exit assistance
- Dr. Ofer M., The Haifa Life Science Innovation Hub, Consultant to Aviva on Biotech in Israel, referrer of PomiCell to LPBI Group
- Dr. A. F-A, MD, PhD, Universidad Complutense de Madrid, Molecular Pathology and Biology of Cancer Cells, Surgical Oncology – Seeker of Partnership with LPBI Group and his start up http://www.ribograma.org
Aviva will present 1 new Internal relations executive Joining LPBI Group and presenting at the meeting:
- Dr. Joel Shertok had joined LPBI Group’s Business side working on automation/digitization of the Global Sourcing Process for M&A and LPBI Group’s Exit using AI technology for 12 industries
Presentations on Skype on 1/14/2020 11AM EST:
- FOUR Presentations [Three external, One internal]
- TWO Commentaries [by External relations]
A. Presentations by EXTERNAL parties requesting Partnership with LPBI Group:
1. AI in Pharma – Israeli start-up’s, CEO, Boaz B. PomiCell.com
2. Oncology Drug Development Madrid-based start up’s CEO, A. F-A, MD, PhD, www.ribograma.org
All external relations will consider the following:
- Do they wish to consider building relations with the two start ups presenter and their start up based on their expertise and their NETWORKS
B. Presentations by parties harnessing OWN expertise for LPBI Group’s Exit efforts
External
3. A. Bahl, ex-Novartis – Presentation on Exit Strategy for LPBI Group – Consideration of relations with LPBI Group
Internal
4. Dr. Joel Shertok had joined LPBI Group’s Business side – Presentation on BOT-based M&A Prospecting Process for LPBI Group
C. Commentaries – Advisory Assistance with LPBI Group’s Exit Efforts
4. Dr. Mak, ex-Pfizer – Comments – Consideration of relations with LPBI Group
5. Ofer Markman, Haifa Biotech Hub – Comments – Consideration of relations with LPBI Group
- Do the Commentary providers advise LPBI Group to stay focused on its core technology for the Exit or
- also to consider Partnerships with presented start up for Reputation and other externalities that will benefit the EXIT
ALL Internal presentations on Skype on 1/14/2020 1PM EST:
- If time will become very limited D. will be conducted at a TBD nest INTERNAL Virtual meeting
5. Dr. Joel Shertok had joined LPBI Group’s Business side working on automation/digitization of the global sourcing process for M&A prospects using AI technology for 12 industries
D. Exit update: 2019 Summary & 2020 Plans
6. Rick – Updates: IB, Crain, SelectHealth, see, below
7. Gail – Communications initiatives, see, below
8. Aviva – 2020, see, below
Part 1: Potential Partnership with Israeli AI in Pharma
An Israeli AI company will present
1. Synergies between their technology and LPBI Group three IP Asset Classes:
– Content in the Journal
– Content in the e-Books
– Content in the e-Proceedings
2. Discussion on a Demo to be created for Pilot study with Healthcare Insurance Payors in the US
3. Rick Mandahl will lead the Discussion on SelectHealth and Intermountain Healthcare System
Contact: CMO, SelectHealth (Oncology), Dr. Roy G.
Part 2: Potential Partnership with Oncology Drug Discovery start up in Madrid
Dr. A. F-A, MD, PhD, Universidad Complutense de Madrid, Molecular Pathology and Biology of Cancer Cells, Surgical Oncology – Seeker of Partnership with LPBI Group and his start up Ribograma.com
- Presentation of Oncology Drug Discovery based on new pathways
A. FERREIRA-ALEMAO MD PhD
INTERNAL PRESENTATIONS – MAY REQUIRE another meeting
Part 3: Internal Presentations: Gail
— Gail to interview Bernadette as a Key Opinion Leader (KOL) in e-Scientific Publishing for an article to market her and Gail and LPBI Group – Rick’s Follow Up??
— Gail to decide if to interview Aviva as a KOL in e-Scientific Publishing
— Gail’s Survery of Website users
Part 4: Internal Presentations: Rick
Rick’s will present HIS SHARE in Business Side Plan for LPBI Group’s Business Development for Exit
– Past: Business Plan involvement
– Present: IB, Crain, SelectHealth
– 2020: Personal Plan on contributions to LPBI Group’s BD and Exit
Part 5: Internal Presentations: Aviva
Aviva will present Agenda on
A. Aviva will introduce her Business Development Goals for 2020 Q1
B. Development of Inbound Marketing. See Link for Inbound Marketing for Beginners – CloudApp
https://www.getcloudapp.com/blog/inbound-marketing-beginners#.XdVI16eJUug.twitter
six inbound marketing channels we outlined:
- Blogging
- Video Marketing
- Social Media Marketing
- Email Marketing
- Search Engine Optimization (SEO)
- Live Events
B.1 the Audio Gail arranged for a Radio Station in NJ
– Interviews: Dr. Williams, Aviva, Irina
– Interviews: All Scientists
– Interview Dr. Pearlman
– Interview Prof. Feldman
B.2 Development of Inbound Marketing Plan of LPBI Group’s Contents using each of the techniques/application in the link above for selected Research Categories in the Journal
B.3 Do Same as 5.1.2 for BioMed e-Series:
Series A: AUDIENCE in Cardiovascular, all Cardiologists in the Community
Series B: Genomics
– consider publishing eTOCs of Genomics Volume 1 and Volume 2 in
GenomeWeb
Series C: AUDIENCE in Oncology
Series D: AUDIENCE in Metabolomics & Infectious Diseases
Series E: AUDIENCE for Precision Medicine targeting Forums for
– Voices of Patients – Volume 1
– 3D BioPrinting – Volume 4
– Breakthroughs in Medicine – Volumes 2 and Volume 3
@@@@
10/15/2019
Meeting held
8/13/2019
Agenda for SKYPE on 8/13, 2019 at 11AM EST – ALL FIT MEMBERS – Attendance is a MUST
Part A: Scientist Unit – FIT Members provide updates
- Dr. Williams
- Genomics Volume 2, Part 7 & Part 8 Updates
- WordPress.com – removal of Ads from a Scientific Journal on a Business account
- Ongoing article publishing and article updates
- Professor Feldman
- Genomics Volume 2, Part 5: Evolution and Genomics – NGS
- Editorials for Genomics Volume 2
- Interview with Gail – last week in Auagust
- Dr. Dror Nir
- Genomics Volume 2, Part 3: AI, Section 3.5 ML Algorithms in Medicine
- Dr. Saha and Dr. Irina Robu
- Please make list of all your articles in the Journal SINCE 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
- Any comments
Part B: Business Unit
- Rick – Latest on
- IB Briefing to the Team
- Lessons from Section #13
- Vision on Business Development
- Questions to the Board & Aviva
- List of Accomplishments since 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
- Gail – Latest on
- Implications of IB Briefing to the Team on Marketing Communication role
- Lessons from Section #13
- Vision on Marketing Communication
- Questions to the Board & Aviva
- List of Accomplishments since 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
- Amnon – Latest on
- Implications of IB Briefing to the Team on Strategy
- Lessons from Section #13
- Vision on Strategy
- Questions to the Board & Aviva
- List of Accomplishments since 6/11/2019 – Update for https://pharmaceuticalintelligence.com/2019-vista/fit-members-who-works-on-what/
Part C: Board Members and Aviva
ALL FIT MEMBERS – PLEASE STUDY and be ready to discuss your own inputs and comment on all other contents related to PRICING as presented in the LINK, below
All Inputs in Consideration for Pricing LPBI Group’s IP Three Classes of Assets
Curator: Aviva Lev-Ari, PhD, RN
1. We plan to have our 1st Final Improvement Team (FIT) Skype meeting the 2nd half of May 2019
2. Please Record your constrains inside this table for scheduling this Skype
| Acronyms | Name | e-Mail of 12 Final Improvement Team (FIT) Members | TRAVEL
NOT Available |
Nearest availability is |
| ALA | Aviva Lev-Ari, Founder | AvivaLev-Ari@alum.berkeley.edu | In NYC 4/24 – 4/29
5/3 Podcast interview on e-Book 3D BioPrinting In May 2019 I am available EVERY day _____________ |
In May 2019 I am available EVERY day |
| MWF | Marcus W. Feldman, Member of the Board | mfeldman@stanford.edu |
in Israel until May 8. I have some commitments during the next week _____________ |
5/9 -5/21 |
| JDP | Justin D. Pearlman, MDMEPhD,
Senior Editor |
jdpmdphd@gmail.com | ||
| SJW | Stephen J. Williams, PhD,
Acting Member of the Board, Senior Editor |
<sjwilliamspa@comcast.net | 5/3 Podcast interview on e-Book 3D BioPrinting
____________ |
5/5
5/7-5/21 |
| DR | Dr. Dror Nir
EAW, Co-Editor |
drornir0305@gmail.com | 5/6 – 5/16 | 5/5
5/17 on |
| IR | Irina Robu, PhD, EAW | irina.stefania@gmail.com | 5/3 Podcast interview on e-Book 3D BioPrinting
___________ |
5/5 – 5/14 |
| SS | Dr. Sudipta Saha, EAW, Co-Editor | mailto:sudiptasaha1977@gmail.com | ||
| GST – Business side | Gail Thornton, Co-Editor, Marketing communications | gailsthornton@yahoo.com | 5/3 Podcast interview on e-Book 3D BioPrinting
____________ |
5/10
5/14 |
| RM – Business side | Rick Mandahl, Business Development & Marketing Research | rmandahl@gmail.com | 5/6, 5/16, 5/17 | |
| AD– Business side | Amnon Danzig | amnon.danzig@gmail.com |
In NYC for Conference May 12-18, 2019 ___________ |
5/1 – 5/12 |
| AS | Adam Sonnenberg | mailto:Adamsonnenberg@hotmail.com | Educ. leave till 5/19/2019
_________ |
|
| LHB | Dr. Larry Bernstein | larry.bernstein@gmail.com | Medical leave
___________ |
@@@@@
See LPBI Group New which is updated weekly
June 2017
MON, June 2017 – Aviva presented to Number 1 in the Scientific Publishing Corporation
Resources used included the following:
January 2017
MON, January 2
TUE, 1/3 – AVIVA MEETS on Skype MH of Exo-incubator
WED 1/4
THU 1/5 — TEAM MEETING 3PM EST ON SKYPE, in attendance MH and RM of Exo-incubator. Presentations by David and Irina
FRI 1/6 – Aviva meets on Skype Larry Mulligan – Series A, Volume 5, Co-Editor
MON, January 9
TUE, 1/10
WED 1/11
THU 1/12 — TEAM MEETING 3PM EST ON SKYPE – in attendance MH and RM of Exo-incubator – Presentation by Aviva and by Dr. Nir
FRI 1/13
MON, January 16
TUE, 1/17
- Aviva meets on Skype Marc Philouze
- Aviva meets on Skype Tilda
- Aviva meets on Skype Larry Mulligan
WED 1/18
THU 1/19 — Aviva meets with WJ at 9:30AM
TEAM MEETING 3PM EST ON SKYPE in attendance: , in attendance MH and RM of Exo-incubator, Tilda and A. Awan
FRI 1/20 Aviva meets on Skype Mr. Lerner and Mr. Philouze
MON, January 23
TUE, 1/24
WED 1/25
THU 1/26 — TEAM MEETING 3PM EST ON SKYPE
FRI 1/27
MON, January 30
TUE, 1/31
February 2017
WED 2/1
THU 2/2 — TEAM MEETING 3PM EST ON SKYPE
FRI 2/3
MON, February 6
TUE, 2/7
WED 2/8
THU 2/9 — TEAM MEETING 3PM EST ON SKYPE
FRI 2/10
MON, February 13
TUE, 2/14
WED 2/15
THU 2/16 — TEAM MEETING 3PM EST ON SKYPE
FRI 2/17
MON, February 20
TUE, 2/21
WED 2/22
THU 2/23 — TEAM MEETING 3PM EST ON SKYPE
FRI 2/24
MON, February 27
TUE, 2/28
March 2017
WED 3/1
THU 3/2 — TEAM MEETING 3PM EST ON SKYPE
FRI 3/3 – LUNCH at 1PM Aviva and Ronald Dorenbos
MON, March 6
TUE, 3/7
WED 3/8
THU 3/9 — TEAM MEETING 3PM EST ON SKYPE
FRI 3/10
MON, March 13
TUE, 3/14
WED 3/15
THU 3/16 — TEAM MEETING 3PM EST ON SKYPE
FRI 3/17
MON, March 20
TUE, 3/21
WED 3/22
THU 3/23 — TEAM MEETING 3PM EST ON SKYPE
FRI 3/24
MON, March 27
TUE, 3/28
WED 3/29
THU 3/30 — TEAM MEETING 3PM EST ON SKYPE
FRI 3/31
Our Channels for e-Marketing Biotech Conferences are:
- Our Journal +1,031,000 eReaders
http://pharmaceuticalintelligence.com
- Aviva’s – +6000 BIOTECH followers on LinkedIn
http://www.linkedin.com/in/avivalevari
- LPBI Group’s FaceBook Page
http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence
- LPBI Group’s Twitter Account
- Aviva Manages three Groups on LinkedIn
Cardiovascular Biotech & Pharma UK & US Networking Group
https://www.linkedin.com/groups/4357927
Leaders in Pharmaceutical Business Intelligence
https://www.linkedin.com/groups/4346921
Innovation in Israel
https://www.linkedin.com/groups/2987122
- LPBI Group’s Company’s Page on LinedIn
WE ARE ON AMAZON.COM
http://www.amazon.com/dp/B00DINFFYC
http://www.amazon.com/dp/B018Q5MCN8
http://www.amazon.com/dp/B018PNHJ84
http://www.amazon.com/dp/B018DHBUO6
http://www.amazon.com/dp/B013RVYR2K
http://www.amazon.com/dp/B012BB0ZF0
http://www.amazon.com/dp/B019UM909A
http://www.amazon.com/dp/B019VH97LU
http://www.amazon.com/dp/B071VQ6YYK
@@@@@
AUGUST 2016
August 1 MON
August 2 TUE Aviva in Hudson River Valley
August 3 WED Aviva in Hudson River Valley – No Team Meeting
August 4 THU Aviva in Hudson River Valley – No Team meeting
August 5 FRI Aviva in Hudson River Valley
August 8 MON Aviva is coming back
August 9 TUE
August 10 WED
August 11 THU – Team meeting – AUGUST 11, 2016 at 9AM
August 12 FRI
August 15 MON
August 16 TUE
August 17 WED
August 18 THU Team meeting – AUGUST 11, 2016 at 9AM
August 19 FRI
August 22 MON
August 23 TUE
August 24 WED
August 25 THU – Discussion on Program Solicitation – NCI
https://sbir.cancer.gov/funding/contracts/currentcontracts?cid=eb_govdel
PHS2017-1
*Deadline for PHS 2017-1 solicitation is October 21, 2016.
For more information about this solicitation please see the Guide Notice NOT-OD-16-123.
Submit your application using the Contract Proposal Submission (eCPS) website. No other method of proposal submission is permitted.
The PHS 2017-1 solicitation included 15 contract topics released by NCI:
- NIH/NCI 355: Cell and Animal-Based Models to Advance Cancer Health Disparity Research
- NIH/NCI 356: Tools and Technologies for Monitoring RNA
- NIH/NCI 357: Innovative Tools for Interrogating Tumor Microenvironment Dynamics
- NIH/NCI 358: Modulating the Microbiome to Improve Therapeutic Efficacy of Cancer Therapeutics
- NIH/NCI 359: Technologies for Differential Isolation of Exosomes and Oncosomes
- NIH/NCI 360: Manufacturing Innovation for the Production of Cell-Based Cancer Immunotherapies
- NIH/NCI 361: Highly Innovative Tools for Quantifying Redox Effector Dynamics in Cancer
- NIH/NCI 362: Informatics Tools to Measure Cancer Care Coordination
- NIH/NCI 363: Connecting Cancer Caregivers to Care Teams: Digital Platforms to Support Informal Cancer Caregiving
- NIH/NCI 364: Methods and Software for Integration of Cancer Metabolomic Data with Other –Omic and Imaging Data
- NIH/NCI 365: Imaging Informatics Tools and Resources for Clinical Cancer Research
- NIH/NCI 366: Clonogenic High-Throughput Assay for Screening Anti-Cancer Agents and Radiation Modulators
- NIH/NCI 367: Predictive Biomarkers to Improve Radiation Treatment
- NIH/NCI 368: Molecularly Targeted Radiation Therapy for Cancer Treatment
- NIH/NCI 369: Development of Pediatric Cancer Drug Delivery Devices
View past contract opportunities.
Ms. Tiffany Chadwick
Procurement Analyst
Office of Acquisitions
E-mail: ncioasbir@mail.nih.gov
Please reference solicitation PHS 2017-1 and the Topic number with any questions.
August 26 FRI
August 29 MON CHI’s Conference on ImmunoTherapy, Marriott LongWharf
August 30 TUE CHI’s Conference on ImmunoTherapy, Marriott LongWharf
August 31 WED Aviva and David are visiting Dr. Nir
September 1 THU Team Meeting
September 2 FRI
September 5 MON HOLIDAY
September 6 TUE
September 7 WED
September 8 THU Team meeting at 9AM
September 9 FRI
September 12 MON
September 13 TUE
September 14 WED
September 15 THU Team meeting at 9AM
September 16 FRI
September 19 MON Aviva and Dr. Williams at … till 9/22
CHI’s 14th Annual Discovery on Target: Preliminary Agenda Available and Exclusive Discount to attend Boston’s Discovery on Target (September 19-22, 2016)
Understanding CRISPR: Mechanisms and Applications: CHI, September 19-22, 2016, Westin Boston Waterfront, Boston
September 20 TUE
September 21 WED
September 22 THU last day Discovery on Target
September 23 FRI
September 26 MON
September 27 TUE
September 28 WED – Team meeting at 9AM
September 29 THU
September 30 FRI
October 3 MON Aviva’s Holiday
October 4 TUE Aviva’s Holiday
October 5 WED
October 6 THU Team meeting at 9AM
October 7 FRI
October 10 MON
October 11 TUE
October 12 WED Yom Kippur
October 13 THU Team meeting at 9AM
October 14 FRI
October 17 MON
October 18 TUE Aviva at EmTech @MIT
October 19 WED Aviva at EmTech @MIT
October 20 THUAviva at EmTech @MIT
October 21 FRI
October 24 MON
October 25 TUE
October 26 WED
October 27 THU Team meeting at 9AM
October 28 FRI
October 31 MON
November 1 TUE
November 2 WED
November 3 THU Team meeting at 9AM
November 4 FRI
November 7 MON
November 8 TUE
November 9 WED
November 10 THU Team meeting at 9AM
November 11 FRI
November 14 MON
November 15 TUE
November 16 WED
November 17 THU Team meeting at 9AM
November 18 FRI
November 21 MON
November 22 TUE
November 23 WED
November 24 THU — THANKSGIVING
November 25 FRI
November 28 MON
November 29 TUE
November 30 WED
DECEMBER 2016
December 1 THU Team meeting at 9AM
December 11 FRI
December 14 MON
@@@@@@
AUGUST 2015
#1: date: 8/13/2015 DONE
Presenter: Aviva
Topic: Medical 3D Printing Applications & Technologies, Tools & Processing
#2: date: 8/20/2015 CONFIRMED – DONE
Presenter: Steve Lerner
Topic: Medical 3D Printing & Programmable Sensors
#3: date: 8/27/2015 – DONE
Presenter: Dr. Pearlman
Topic: Medical 3D Printing: Thought Leadership for Products and Services
#4: date: 9/3/2015 – DONE
Presenter: Dr. Stephen J Williams
Topic: Medical 3D Printing and BioInks
#5: date: 9/10/2015 – Aviva’s Presentation
AGENDA for 9/10
- GDE
- Matrix Organization for M3DP
http://pharmaceuticalintelligence.com/2015/08/26/lpbis-m3dp-matrix-organization/
#6: date: 9/24/2015 – DONE
Presenter: Irina Robu, PhD
Topic: Medical 3D Printing for Tissue Engineering
#7: date: 10/1/2015 CONFIRMED
Topic: Presenter: Irina Robu, PhD
Medical 3D Printing for Tissue Engineering
#8: date: 10/8/2015 CONFIRMED
Presenter: Bill Zurn
Topic: Medical 3D Printing and MEMS
#9: date: 10/15/2015 CONFIRMED
Presenter: Tilda Barliya, PhD
Topic: Medical 3D Printing and Tissue Engineering in Israel
#9A: date: 10/16/2015 THREE Presentations CONFIRMED
Presentation #1: Rosalind Codrington, PhD – 60 minutes
Cell Selection using Intracellular Targets
Presentation #2: Evelyna Cohn, PhD – 30 – minutes
Glycoprotein and 3D BioPrinting
Presentation #3: Stephen J Williams, PhD and Dharmendra Goswami, PhD – 30 Minutes
Gene Therapy: CRISPR and 3D BioPrinting
October 19, 2015
8AM EST -Aviva Phone Call with Dr. Liane Patt
2PM EST – Skype: Dr. Saul Yedgar, HUJI with Gerard & Aviva
October 20, 2015
9AM EST – Skype: Dr. Yaniv Dolev, CEO Moebius with Gerard & Aviva
October 21, 2015
THIS MEETING WILL BE RESCHEDULED
8AM EST = 2PM Swiss Time Skype Strategy
30 minutes Teaser Template [Fosun, Sunshine Capital] –
30 minutes Journal Strategy for George Institute
We will be working on that with our Business Development Team Members:
– Arie Berger, BD, China ATTENDED
– [unable to attend] Gerard Loiseau, Co-Founder, GDE and BD, Switzerland and France – Will ALSO represent you in his territory ABSENT
– Silvester Werring, BD, Benelux and Scandinavia – Will ALSO represent you in his territory ABSENT
And we will be working on that with our R&D Team Members on GDE’s M3DP
– Dr. Stephen J Williams, R&D Gene Editing, Biologics, Tissue Engineering – NOVEL Applications for 3D Printing – ATTENDED
– Dr. Pearlman, R&D in Medical Devices — NOVEL Applications for 3D Printing – ABSENT
October 21, 2015 @ 10:00 PM EST
Topic: Skype Stephen J. Williams, Ph.D. with Aviva Lev-Ari, Ph.D., R.N. on GDE
October 22, 2015 @9:30 AM EST
Attendees: ALL M3DP Team
Absents: Dr. Codrington, on route Spain to UK
Up to 30 minutes Late CONFIRMED arrival: Dr. Cohn, Dr. Dragoi, Dr. Goswami
Aviva will start with the Agenda
a. GDE’s Calendar: OUR Meeting Management Tool http://pharmaceuticalintelligence.com/calendar/
b. December 2015 – January 2016: Lecture Series INTERDISCIPLINARY Project on BioMEMS
c. Team Voting on NDA AMONG Team Members
d. Investors Relations
b. ABOVE — >>>Team member ADD to calendar YOUR SELECTED Thursday and the TOPIC, see Below 2.1 to 6.3
October 22, 2015 @10:35 AM EST NOT DELIVERED
Danut Dragoi, PhD – PRESENTATION POSTPOSED – 50% TO BE DELIVERED IN EACH OF THE FOLLOWING TWO MEETING SESSIONS
Topic: Medical 3D Printing and Metals in use in Medical Devices
October 22, 2015 @11:30 AM EST
Dharmendra Goswami, PhD and Stephen J. Williams, Ph.D
Topic: Gene Editing: 40 minute preview of November 12 talk
October 22, 2015 1PM EST = 7PM Swiss Time
30 minutes Teaser Template & European Investor House
10 minutes Scientific Delegations to Geneva and Barcelona (Gerard)
30 minites George Institute AGENDA
We will be working on that with our Business Development Team Members:
– Arie Berger, BD, China
– Gerard Loiseau, Co-Founder, GDE and BD, Switzerland and France – Will ALSO represent you in his territory
And we will be working on that with our R&D Team Members on GDE’s M3DP – our INTERIM VPs
– Dr. Stephen J Williams, R&D Gene Editing, Biologics, Tissue Engineering – NOVEL Applications for 3D Printing
– Dr. Pearlman, R&D in Medical Devices — NOVEL Applications for 3D Printing
October 23, 2015 @ 8:30AM EST Skype
Skype session with Dr. Andrew DePristo
- Gerard
- Aviva
October 23, 2015 @ 9:30AM EST Skype
Research Funding for Diagnostics Kits Development
- Dr. Codrington – Magnetic Beads for Intra cellular cell selection – MEETING TO BE RESCHEDULED TO 10/30/2015 @9:30AM EST NOT DELIVERED
- Dr. Cohn – Multiple Sclerosis – PRESENTATION DELIVERED
- YOUR R&D PLAN
- YOUR PROTOCOL
- YOUR FUNDING NEEDS ITEMIZED
Attendees:
- GérardLoiseau
- Dr. Irina Robu, PhD
- Dr, Danut Dragoi
- Aviva
October 26, 2015
Skype at 10:30AM EST = 4:30AM Israel Time with LIPOMEDIX
- Prof. Alberto Gabizon
- Dr. Patricia Ohana
- Gerard
- Aviva
Skype at noon EST with Dr. Gilad Evrony
- Aviva
- Gerard
October 27, 2015
Stephen J. Williams [UNAVAILABLE]
10AM EST Skype with Moebius
- Yaniv Dolev
- Gerard
- Aviva
October 28, 2015
7AM EST Skype
- Gerard
- Phillip Carrrigan
NOT CONFIRMED Yigal Stav, CEO of Tiltan Pharmaceutics, drug for Pancreatic Cancer
3:30PM Skype
- Aviva
- Dr. Dharmendra Goswami
October 29, 2015 @9:30AM EST = 2:30PM Swiss Time
Presenter: Gerard Loiseau, ESQ
Topic: Medical 3D Printing and Dental
October 29, 2015 @11AM EST
Presenter: Danut Dragoi
Topic: Medical 3D Printing and Metals in use in Medical Devices
POSTPONED: Dr. Ayal Hendel and Prof. Marc Feldman, Stanford University
Topic: CRISPR and 3D Printing
Aviva: Staff Meeting
Series E, Volume Four: Medical 3D BioPrinting – The Revolution in Medicine | Leaders in Pharmaceutical Business Intelligence
2PM Skype with Dr. Dolev, CEO Moebius
- Yaniv DOlev
- Gerard
- Aviva
October 30, 2015
Stephen J. Williams, Ph.D. [UNAVAILABLE]
8:00 AM EST Gerard and Aviva Skype with Ygal Stav, Tiltan Pharmaceutics
9:00 AM Dr. Codrington Presentation 9:00AM EST = 1:30PM UK = 2:30PM Swiss Time
Investment Requirements & Research Plan
- Aviva
- Gerard
- Evelina Cohn
- Danut
- Irina
- Dr. Raphael Nir
NOVEMBER, 2015
November 2, 2015
Aviva all day @MIT
November 3, 2015
Gerard not available from 4:00pm to 9:30pm Swiss Time
Aviva all day @MIT
November 4, 2015
Aviva all day @MIT
November 5, 2015 Meeting will start at 10AM EST = 4PM SwissTime
#12: date: 11/5/2015 CONFIRMED
Presenter: Dr. Raphael Nir
Topic: Medical 3D Printing and Cytokines
November 6, 2015
November 9, 2015
8:30AM EST Skype
- Gerard
-
Sudhir Ahluwalia
- Aviva
11:00AM EST = 5:00PM Swiss Time Skype with Pedro Fernandes
- Aviva
- Gérard
12:15PM EST Skype with Steven R. Gerbsman,
Gerbsman Partners Phone: 415.456.0628 Cell: 415.505.4991
- Gerard
-
Steven R. Gerbsman
- Aviva
November 10, 2015
@8AM EST = 2PM Swiss Time Skype
Tuesday, November 10, 2015 at 8:00AM EST – 9:00AM EST
Dial in: +41 21 588 09 41 Press 1 for the conference call
or +972 3 777 34 94 –
room 6464 – code 1201
- Laurent Choppe
- Gerard
- Aviva
@8:30AM PST = 11:30AM EST = 5:30PM Swiss Time
Skype with
- Bryan Dow
- Gerard
- Aviva
November 11, 2015
8:00AM EST = 2:00PM Swiss Time = 3:00PM Israel Time
Skype with Tiltan Pharma :
- Shmuel (Muli) Ben-Sasson Office: +972-2-675-8338 ; Cell: +972-54-23-25-254
- Yigal Stav
- Aviva
- Gérard
November 12, 2015
#13: date: 11/12/2015 POSTPONED
Presenter: Dr. Dharmendra Goswami
Topic: CRISPR and The Future of Gene Therapy
November 13, 2015
8AM EST = 1PM UK = 2PM Swiss Time
Presentation by Dr. Codrington – Her Research Plan
Attendees: ALL TEAM R&D in Biologics @M3DP, Aviva & Gerard
10AM EST = 3PM UK = 4PM Swiss Time
FOLLOW UP MEETING TO DISCUSS THE INPUT OF EACH TEAM MEMBER TO Dr. NIR’S CONCEPT OF
- A DEVICE FOR BETATROPIN-DRIVEN PANCREATIC BETA CELLS INSULIN PRODUCTION STIMULATION
Attendees: ALL M3DP TEAM, Aviva & Gerard
Stephen Williams Unavailable
November 16, 2015
8AM EST = 2PM Swiss Time Skype Session
- Gerard
- Aviva
November 17, 2015
8AM EST = 2PM Swiss Time Skype Session with Sheldon Singer, Ed.D, MS
Tech Valley Partners LLC
Applied Strategic Consulting
- Gerard
- Aviva
- Dr. Williams
- Dr. Pearlman
11AM EST = 5PM Swiss Time Skype Session with Gerard
- Goeffrey Goodell
- Aviva
Both at my Office in person
Aviva @5PM PMC Reception in Boston
November 18, 2015
The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Joseph B. Martin Conference Center of the Harvard New Research Building at Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA
Real Time Conference Press Coverage: Aviva Lev-Ari, PhD, RN
www.personalizedmedicineconference.org
November 19, 2015 No Presentation No Staff Meeting
November 19, 2015
Gerard NOT available after noon EST = 6PM Swiss Time
The 11th Annual Personalized Medicine Conference, November 18-19, 2015, Joseph B. Martin Conference Center of the Harvard New Research Building at Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA
Real Time Conference Press Coverage: Aviva Lev-Ari, PhD, RN
www.personalizedmedicineconference.org
6PM @ KI @MIT
- Aviva
November 20, 2015
Gerard NOT available after noon EST = 6PM Swiss Time
8AM EST = 2PM Swiss Time Skype Session
-
Daniele Zanotti, CEO presso KEPHALIOS, Paris, CVD Medical Devices, MBA INSEAD
- Gerard
- Aviva
November 23, 2015
9AM EST = 3 PM Swiss Time
- Gérard
- Aviva
Publishing
Joint Venture
GDE Stratgy
November 24, 2015
Aviva Not Available 8AM EST to 2PM EST – NWH
November 25, 2015
Aviva Not Available 8AM EST to 2PM EST – OCB
2PM EST VIDEO Conferencing with
- Pedro
- Gerard
November 26, 2015
THANKSGIVING
November 27, 2015
November 30, 2015
Skype with Melvin Prenovitz 9AM EST = 3PM Swiss Time
- Aviva
- Gerard
Skype with Lauren Holt 10AM EST = 4PM Swiss Time
- Aviva
- Gerard
Skype with Bill Zurn noon in Boston, 9AM in CA and 6PM in Swiss Time
- Aviva
- Gerard
DECEMBER 2015
December 1, 2015
December 2, 2015
December 3, 2015 #15: date 12/3/2015 9AM EST = 4PM Israel Time
- POSTPONED — Dr. Saul Yedgar, Hebrew University, Inventor of Multifunctional NSAID
Mechanism of Action: Multifunctional NSAID & its Multiple Indications
#15: date 12/3/2015 CONFIRMED
- Presenter: Stephen J. Williams, Ph.D
CrowdFunding sources for Research and Startups
December 4, 2015
Friday 6AM EST SKYPE = 1PM Israel = noon Swiss Time
- Dr. Saul Yedgar
- Aviva
Friday 8AM EST SKYPE = 2PM Swiss Time
- Gerard
- Dr. Raphael Nir
- Aviva
Friday 9AM EST SKYPE = 3PM Swiss Time = 4PM Israel – TEAM presentation Drug-Device for Insulin
- Gerard
- Dr. Raphael Nir
- Aviva
Friday 11AM EST SKYPE = 5PM Swiss Time
Dan Trajman <dan@dt-studio.com>
Skype or on FaceTime
- Gerard
- Dan Trajman
- Aviva
December 5, 2015
December 6, 2015
December 7, 2015
9:00AM EST = 3:00PM Swiss Time = 10:00PM Singapore
- Aviva
- Yelena ZEMTSOVA
- Gérard
NOON EST = 6PM Swiss Time
- Gerard
- Dr. Sheldon Singer
- Aviva
December 8, 2015 12/7/2015 Boston: 11:59PM = Midnight in Boston = 6AM Swiss Time = 1PM Hong Kong
- Gerard
-
Alberto Forchielli
- Aviva
December 8, 2015
Gérard not available 6:30PM-9:30PM Swiss Time
9AM EST = 3PM Swiss Time – Skype with
- Gerard
- Dr. Stuart Cantor
- Aviva
December 9, 2015
December 10, 2015 2PM = 7PM UK = 8PM Swiss Time = 9PM Israel Time
Presenter:
Professor Saul Yedgar
Walter & Greta Stiel Chair in Heart Studies
Department of Biochemistry
Hebrew University-Hadassah Medical School
Jerusalem, Israel 91120
“Multi-Functional Approach in Treating Inflammatory/Allergic Diseases”
Guest Attendee – POSTPONED
From Stanford University, Biology Department — Professor Marc Feldman
Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences – BIOLOGY
December 11, 2015 – No change
- Friday 8AM EST = 2PM Swiss Time: Dr. Nir, Gerard, Aviva on the Joint Venture: SBH & M3DP
- Friday 9AM EST = 2PM Swiss Time: Dr. Nir, Gerard, Aviva ALL THE M3DP TEAM
December 14, 2015
Skype – Monday, Dec 14, 12:30PM EST
- Gerard
- Tal Katz
- Aviva
Tal Katz (ex-ValTech)
Mechanical Engineer at Vanrx Pharmasystems Inc.
Vancouver, Canada AreaMedical Devices
Conference Call – Monday December 14th 2PM EST
1-712-775-7031 access code 954-541-684 [host 4332]
- Gerard
- Michael E. Kahn, Sr. VP UBS
- Aviva
December 15, 2015
Gérard not available after 1:00PM EST
Skype 9AM EST to 12:45PM EST – Operations Management: GDE Enterprises
- Gerard
- Aviva
Skype 3PM EST
- Talia
- Aviva
December 16, 2015
December 17, 2015 @ 9:30 AM
A. Presenter: Dr. Codrington
Immunology, Magnetic Beads and 3D BioPrinting and Patent Award in UK –Claims and Provisions
B. Aviva’s Discussion of the LINKS above
Part 2. READING materials for THU
December 18, 2015
- Friday 8AM EST = 2PM Swiss Time: Dr. Nir, Gerard, Aviva on the Joint Venture: SBH & M3DP
- Friday 9AM EST = 2PM Swiss Time: Dr. Nir, Gerard, Aviva ALL the M3DP TEAM
- Protected: GDE’s Inflammation Drug Discovery and Positioning Project http://pharmaceuticalintelligence.com/2015/12/10/gdes-inflammation-drug-discovery-and-positioning-project/
-
Team to REVIEW LINKS
December 21, 2015
Gérard not available from 11AM EST until 1PM EST
Skype session @8AM Boston = 2PM Swiss Time = 3PM Israel Time
- Gerard
- Joe van Zwaren
- Aviva
Skype session @9:30AM Boston = 3:30 Swiss Time = 4:30PM Israel Time
- Gerard
- Yossi Mograbi
- Aviva
Skype session @2:30PM Boston = 8:30PM Swiss Time
- Gerard
- Dr. Raphael Nir
- Aviva
December 22, 2015 – TUE at 8AM
- Gerard
- Aviva
- Steven Schneier
December 23, 2015
December 24, 2015 – Holiday
December 25, 2015
Christmas Day
December 28, 2015
9:30AM EST – 11:45AM EST Skype with
- Gerard
- Dr. Stuart Cantor
- Aviva
noon EST – 2PM EST Skype with
- Gerard
- Joe van Zwaren
- Aviva
2PM EST – 3PM EST Skype with
- Gerard
- Yossi Mograbi
- Aviva
December 29, 2015
9AM EST Skype with Sheldon Singer
noon EST Skype Talia & Aviva — Tue Dec 29, 2015 7pm – 8pm Jerusalem = Noon Boston
December 30, 2015
December 31, 2015 – Holiday
JANUARY 2016
FRIDAY 9AM EST — Presentations on JVIP
| Name | Date | FRIDAY Joint Venture Presentation Topics | Comments |
| Evelina | 2/5/2016 | search the common pathways of adipose cells vs pancreatic and liver cells. What they have in common what they have different and how we can stimulate beta cells insulin production.
– growth of adipose cells or – transform them by inhibition of certain pathways. – what is the mechanism. |
|
| Dr. Williams | 1/29/2016 | what are the factors responsible for inducing insulin production vs differentiating in other cell types | |
| Dr. Nir | 2/5/2016 |
|
|
| 2/12/2016 | NO MEETING | ||
| Dr. Irina | 2/19/2016 | how adipocytes derived from brown fat can be used as a cell source or if they can be differentiated into betacells. | |
| 2/19/2016 | |||
| Dr. WIlliams | 2/19/2016 | PPAR-gamma | |
| Dr. Cohn | 2/19/2016 | Adipose Tissue vs Encapsulation of Beta Cells – MIT Research
Breakthrough Research on Encapsulated pancreatic cells offer possible new diabetes treatment. |
|
| Danut | 2/26/2016 | TBA |
THURSDAY Presentations on BioMEMS
‘Early identification of biomarkers for the delivery of personalised therapy’
| Date | AM EST Time | Name | Topic |
| 1/7/16 | 9:30 | Dr. Pearlman | Medical Implants and Surgery |
| 1/7/16 | 10:30 | Dr. Irina | Engineering Tissue, Cell tissue engineering with BioMEMS |
| 1/14/16 | 10:00 | Dr. Evelina Cohn | “Promising molecules for cell detection in environmental and clinical samples:DNA/peptide co-assembly” |
| 1/21/16 | 10:00 | Aviva & Gerard | Oligonucleotide chips & Markets |
| 1/28/16 | 10:00
11:00 |
Dr. Codrington
Dr. Williams |
APS
Tutorial on using WordPress on our Platform |
| 2/4/16 | 10:00 | Dr. Stu Cantor | 6 Bio-MEMS in medical implants and surgery |
| 6.1 Implantable microelectrodes | |||
| 6.2 Microtools for surgery | |||
| 6.3 Drug delivery | |||
| 2/11/16 | No Meeting | ||
| 2/18/16 | 10:00 | Dr. Williams
Bill Zurn |
BioMems cell signaling PCR, micro arrays and beyond
Medical MEMS |
| 2/25/16 | 10:00 | Dr. Williams | TUTORIAL E-PUBLISHING: CURATION |
| 11:30 | Dr. Danut Dragoi | BioMEMS based Optical Sensors | |
| 3/3/16 | 10:00 | TBA | |
| 10-Mar | 10:00 | Dr. Nir | TBA |
| 3/17/16 | 10:00 | Dr. Tilda | TBA |
| 24-Mar | 10:00 | Dr. Sant | TBA |
| 31-Mar | 10:00 | ||
WE ARE ON AMAZON.COM
January 1, 2016 NEW New Year Day
Mon – January 4, 2016
8AM EST Skype session
- Gerard
- Aviva
- Steven Schneier
Tue – January 5, 2016
8AM EST Skype – 2PM Swiss Time – 3PM Israel Time
- Aviva
- Gerard
- Dr. Neta KELA-MADAR
9AM EST Skype session
- Aviva
- Dr. Singer
WED – January 6, 2016
9:30AM EST Skype – 3:30PM Swiss Time
- Aviva
- Gerard
- Dr. Stuart Cantor
THU – January 7, 2016
January 7, 2016 – Reading material on
Research on Scaffolds to support Stem Cells prior to Implantation
9:30AM EST Dr. Pearlman – Confirmed
BioMEMS TOPIC 6: Medical Implants and Surgery
10:30AM Dr. Irina Robu
Engineering Tissue, Cell tissue engineering with BioMEMS
FRI – January 8, 2016 at 9AM EST
Six life science firms land $930k in state grants
The Massachusetts Life Sciences Center has a program – UP :
http://www.masslifesciences.com/programs/international-up/
We should do all effort to submit a CO-program (grant proposal). We can receive in MA $200K.
Any feedback ? Idea ?
It can be ANY organization / company out of the US and a company in MA !!….Obviousely, SBH (as part of our JV) can be the MA company…..
| Dr. Larry H Bernstein, MD, FCAP | Insulin Receptor – Agonists and Antagonists Agents | http://pharmaceuticalintelligence.com/2015/12/18/insulin-receptor-agonists-and-antagonists-agents/ |
| Dr. Rosalind Codrington | · APS
· Gene Cassette |
|
| Dr. Eveline Cohn | PPAR-gamma | |
| Dr. Irina Robu | · Leptin
· PPAR-gamma |
|
| Dr. Stu Cantor | · Betatrophin
· Leptin · PPAR-gamma |
|
| Dr. Stephen Williams | · PPAR-gamma Activators
· Clinical Trials on each of the four · Combination |
· Troglitazone (Parke-Davis)
· Rosiglitazone (GSK) · Pioglitazone (Eli Lilly) · Muraglitazar (BMS) |
January 11, 2016
9PM EST to 11PM EST
- Aviva
- Gérard
Gerard not available from noon EST until 2:00PM EST
January 12, 2016
Gerard not available from 6:00AM EST until 9:30AM EST
Gerard not available from 1:30PM EST until 3:30PM EST
January 13, 2016
Gerard not available from noon EST until 2:00PM EST
9AM EST Confirmed Skype with Dan Trajman <dan@dt-studio.com> @9AM EST
cell 617-320 – 1862
- Gerard
- Dan Trajman
- Aviva
10:30AM EST Confirmed Skype with Gary Casey @ 10:30AM EST
- Gerard
- Gary Casey
- Aviva
January 14, 2016 Dr. Evelina Cohn
Gérard not available after noon EST
“Promising molecules for cell detection in environmental and clinical samples:DNA/peptide co-assembly”
January 15, 2016
8AM EST – Skype
- Gerard
- Dr. Nir
- Aviva
9AM EST
- TEAM PRESENTATIONS
Monday – January 18, 2016
8:30 AM, PST = 11:30AM EST = 5:30PM SWISS TIME – Skype with
- Gerard
- Bill Zurn
- Aviva
TUE – January 19, 2016
Gérard not available after noon EST 18:00 SWISS TIME
WED – January 20, 2016
THU – January 21, 2016 Gerard and Aviva
Oligonucleotide chips
Dr. Williams only available until 11:00 AM
FRI – January 22, 2016
8AM EST – Skype
- Gerard
- Dr. Nir
- Aviva
9AM EST
- TEAM PRESENTATIONS
MON – January 25, 2016 8AM EST
Confirming 1/25 TUE at 8AM EST – Skype with
- Gerard
- Aviva
TUE – January 26, 2016 8AM EST
Confirming 1/26 TUE at 8AM EST – Skype with
- Gerard
- Aviva
TUE – January 26, 2016, 9:30AM EST
9:30 AM EST = 3:30PM Paris & SWISS TIME – Skype with Video with
- Gerard
- Dr. Binah Baum
- Aviva
- Dr. Williams
Gérard not available after 11:00 AM EST till when ??
TUE – January 26, 2016, 2:30PM EST
2:30 PM EST = 8:30PM SWISS TIME – CONFERENCE CALL with
- Nick Hall and other Team Members, Maxim Group
- Gerard
- Dr. Williams
- Aviva
WED – January 27, 2016 Skype 9AM EST = 4PM IL time
- Agmon Porat
WED – January 27, 2016
- 11AM call with Dr. Grannum Sant
- 4PM in Person meeting with Dr. Grannum Sant
THU – January 28, 2016
@10AM EST Dr. Codrington Presentation on APS
@11:00AM EST Stephen J.Williams, Ph.D.
Site Statistics – Tutorial on using WordPress on our Platform
(1/20 11:56 attachment to share with the Team as Instructions)
@noon Aviva’s announcements and Group Discussion
FRI – January 29, 2016
8AM EST – Skype
- Gerard
- Dr. Nir
- Aviva
9AM EST
- TEAM PRESENTATIONS
FEBRUARY 2016
February 1 MON
9AM EST – 3PM SWISS TIME
GDE Enterprises Strategy
- Aviva
- Gérard
February 2 TUE
-
CONFIRMED – 9am Tues Conference Call Aviva & Dr. Singer
Noon EST – 6PM SWISS TIME : The Voice
- Aviva
- Gérard
February 3 WED
9AM EST Skype
- Aviva
- Steven Hamm
noon EST – Skype
- Aviva
- Prof. Saul Yedgar
February 4 THU – 9:30AM Skype
Gérard not available from February 4 until February 8 inclusive
Presenter: Dr. Stuart Cantor
6 Bio-MEMS in medical implants and surgery
February 4 THU – 2PM EST Skype
- Aviva
- Arie Berger
February 5 FRI
Gérard not available from February 4 until February 8 inclusive
8AM EST – In Person in Newton
- Dr. Nir
- Aviva
9AM EST
- TEAM PRESENTATIONS
February 8
Gérard not available from February 4 until February 8 inclusive
Aviva OVERSEAS – on e-mail
February 9
Aviva OVERSEAS – on e-mail
February 10
Aviva OVERSEAS – on e-mail
February 11 THU – NO Skype MEETING
Gerard not available
Aviva OVERSEAS @ Wedding not on e-mail
February 12 – FRI – NO Skype MEETING – Aviva Meets in person Team members in Israel
Aviva OVERSEAS – on e-mail
February 15
February 16
Gérard not available after noon EST – 6PM SWISS TIME
February 17 WED
Gérard not available
February 18 THU @1o:00AM EST Bill Zurn
Medical – Surgical MEMS
February 18 THU @noon EST Dr. Williams:
Human Factor Engineering: New Regulations Impact Drug Delivery, Device Design And Human Interaction
Dr. Williams: postponed to March 17
BioMems cell signaling PCR, micro arrays and beyond
February 19 FRI
8AM EST – Skype
- Gerard
- Dr. Nir
- Aviva
9AM EST
- TEAM PRESENTATIONS
Gérard not available after noon EST – 6PM SWISS TIME
February 22 MON Skype 11AM EST
- Aviva
- Steve Lerner
February 22 MON Skype 1PM EST
- Aviva
- Dr. Nowell
February 23 TUE
9AM EST: Conference Call
- Dr. Singer
- Aviva
10AM EST: Skype Session
- Dr. Roger NOWELL
- Aviva
- Gérard
2PM EST: Skype Session
- Lucian Cojescu
- Aviva
February 24 WED – Skype 8AM
- David Orchard-Webb
- Aviva
February 24 WED – Skype 7AM Pacific, 10AM EST, 4PM SWISS TIME
- Dr. Tammalla
- Gerard
- Aviva
Gérard not available after NOON EST
THU – February 25 THU – 9AM EST – Group meeting
@9:00AM EST Danut Dragoi, PhD
BioMEMS based Optical Sensors
@10:30AM Aviva Presents Vision of Scientist Recruitment for NewCo
[10:15 – 11:15 – when Danut is driving son to School]
@11:30 EST Group discussion on BioMEMS based Optical Sensors
Gérard not available after NOON EST
February 26 – FRI
8AM EST – Skype
- Dr. Nir
- Aviva
9AM EST
- TEAM PRESENTATIONS – Dr. Williams to present the Paper by Dr. Cohn on Adipocytes – To be rescheduled
- Dr. Nir
February 29 Mon
JANUARY, FEBRUARY and MARCH 2016:
M3DP Team Members Presentations on BioMEMS
- 1 History
- 2 Approaches
- 3 Bio-MEMS as Miniaturized Biosensors
- 4 Bio-MEMS for diagnostics
- 5 Bio-MEMS in tissue engineering
- 6 Bio-MEMS in medical implants and surgery
- 7 References
https://en.wikipedia.org/wiki/Bio-MEMS
MARCH 2016
March 1 TUE at noon EST – Skype with
- Aviva
- Dr. Roger Nowell
March 2 WED 11:00 AM EST Skype
-
Mr. Lucian Cojescu, BSEE, MBA – a candidate to our Team
March 2 WED 3:30 PM EST Skype
- Mr. Lucian Cojescu, BSEE, MBA – a candidate to our Team
Beginning March 3, 2016 TEAM MEETINGS ON THURSDAYS AND ON FRIDAYS WILL TAKE PLACE ON SKYPE AT NOON EST
TIME TABLE —->>>>>>> MassChallenge – Boston, Jerusalem, Lausanne
March 29 – April 22: Round 1 Judging: Expert judges assess online applications and provide feedback to entrants. Each application receives scoring and feedback from multiple judges.
May 4 – May 11: Round 2 Judging: Semi-finalist startups deliver 20-minute pitches to panels of judges in Boston, Lausanne, or Jerusalem. Live Q&A followed up by written scoring and feedback.
May 19: Finalist Announcement. The most promising startups are invited to participate in the MassChallenge 2016 accelerator programs as finalists.
June 20 – October 14: Accelerator Program. Access to world-class mentorship, training, office space, funding, marketing, media and other resources.
September 27 – September 29: Pre-final Judging: Finalists pitch to panels of judges highlighting their progress during the accelerator.
October 13 & 14: Final Judging. The top 26 startups pitch to high profile judges, who determine cash awards.
October 27: Israel Awards Ceremony.
November 2: Boston Awards Ceremony.
March 3 THU @ NOON EST Team Meeting
March 4 FRI
11AM EST – Skype
- Dr. Nir
- Aviva
NOON EST
- TEAM PRESENTATIONS
- Dr. Nir
March 7 – MON 10AM EST
- Dr. Yedgar
- Aviva
March 7 – MON 11AM EST
- Todd Johnson, CEO Healthloop – preparation for March 8th from 3PM to 3:30pm EST Aviva interviews Dr. Jordan Shlain, founder of HealthLoop.
- Aviva
March 8 – TUE
10AM EST to 11:00AM EST : Mechanism of Action and all US Patents with time stamp to expiration
- Dr Saul Yedgar – Newton
- Dr. Nir – Newton
- The TEAM – on Skype
11:00 AM EST to 12:00 AM EST : Team Discussion
noon – 1:30PM EST: Meeting
- Dr. Yedgar
- Aviva
- Dr. Nir
1:30PM – 2PM EST: Meeting
- Dr. Yedgar
- Aviva
March 8th from 3PM to 3:30pm EST
- Aviva interviews Dr. Jordan Shlain, founder of HealthLoop.
March 9 – WED
9AM EST : strategy regarding DRUG DISCOVERY on Anti-INFLAMMATORY AGENTS
- Aviva
- Dr. Nir
March 10 THU – NOON EST:
Presentation of the strategy to the TEAM & Team Presentations on Drug Discovery
- Aviva
- Dr. Nir
March 11 FRI NOON EST
- Aviva
- TEAM PRESENTATIONS on BioMEMS
March 11 FRI 4PM EST Skype
- Aviva
- Dr. Williams
- Dr. Adam Dikler, MD, PhD, Jefferson Medical School
March 14
March 15
Florian Kemmerich – Skype at 12:45PM EST
Avinoam Ducler – Skype at 2PM EST
March 16
March 17 THU @NOON EST
Dr. Williams: BioMems cell signaling PCR, micro arrays and beyond
March 18
11AM EST – Skype POSTPONED
- Dr. Nir
- Aviva
NOON EST
- TEAM PRESENTATIONS
- Aviva
March 21
March 22
March 23 WED — Skype at 9AM EST
- Aviva
- Tony McDaniel
March 23 WED — Skype at 10AM EST
- Aviva
- Gail Thornton
March 24 THU NOON EST
Dr. Williams unavailable after 3 PM EST
March 25 FRI 9AM
Good Friday; Gregorian Calendar
NO MEETINGS
- Dr. Williams unavailable
March 28
March 29
March 30
March 31 THU NO MEETING
Aviva @ 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA
April 2016
Dr. Irina
5/2/2016
- KOST’s Smart Polymer, see Drug delivery, above
Aviva
5/2/2016
- Anti-Inflamatory molecules in development, See above link under Drug Discovery
Dr. Irina
5/2/2016
- How adipocytes derived from brown fat can be used as a cell source or if they can be differentiated into beta cells.
Aviva
5/22016
- Review of Drug-Devices in Diabetes
Dr. Williams
4/13/2016
Dr. Evalina Cohn’s presentation on reprogramming adipocytes
April 1 FRI No Meeting
Aviva @ 2016 MassBio Annual Meeting 03/31/2016 8:00 AM – 04/01/2016 3:00 PM Royal Sonesta, Cambridge MA
April 4 at 2PM Conference Call with Yissum
April 5 TUE 7PM EST Skype Avi Dukler
April 6 WED 9AM EST Skype Gideon Meiri
April 7 THU
Aviva Presents: Sygnature Discovery’s research capabilities – Attachment in DD@LPBI Group
Aviva Presents:26 US Patents – akshayabio
http://www.akshayabio.com/pdf/Akshaya_Overview_Web_02_December_2015_Rajan.pdf
Aviva Presents: Target Health Inc., established in 1993, is a New York City-based eCRO
Target Document® (eTMF)
Target e*CRF® (EDC-since 1999)
Target e*Studio® (tech transfer version of Target e*CRF®)
Target e*CTR® (esource; Electronic Clinical Trial Record allows sites to enter data directly, create a source record and is compatible with any edc system)
Target e*CTMS™
All of our software is web based, 21CFR Part 11 compliant and compatible with both the EMA reflections document on eSource and the FDA final eSource guidance.
April 8 FRI NOON EST
- Dr. Nir
- Aviva
- Dr. David Orchard-Webb
- Entire Team
60 Minutes – Own research – 5 articles in Immune-Oncology
60 minutes – CAR-T and TCRL
60 minutes – Team discussion
- Dr. Raphael Nir
- Dr. Williams
April 11
April 12 @9:45AM EST Aviva & Gideon Meiri -Skype
April 13 @9:00AM EST Aviva and Khoja, Afshan (BOS-WSW)
April 13 – noon – Team Meeting – postponed
April 14 THU – noon – Team Meeting
Presentation by a Portfolio of 26 Patents in Immunology
Rajan George, Ph.D, President & Chief Scientific Officer, Akshaya Bio Inc. Edmonton, Alberta, Canada
April 14 THU @4:30-5:30PM EST Aviva and Alex Satzman on Skype
April 15 FRI
April 18
April 19
April 20 WED
11-12 AM Aviva and SJ Williams (internal on CHI)
NOON EST – Team Meeting
April 21 THU NOON EST – Team Meeting
April 22 FRI PASSSOVER Start – Aviva is unavailable – NO MEETING
April 25 – Aviva is unavailable – NO MEETING
Aviva @
2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston
April 26 – Aviva is unavailable – NO MEETING
Aviva @
2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston
April 27 – Aviva is unavailable – NO MEETING
Aviva @
2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston
April 28 THU NOON EST – Team Meeting
Mid-Atlantic Laboratory Robotics Group Meeting with Demonstrations of bioprinting equipment Dr. Williams may not be available for afternoon
April 29 FRI (Orthodox Good Friday; Orthodox Easter May 1)
MAY 2016
May 2 Mon
May 3 Tue
May 4 WED NOON EST – Team Meeting
May 5 THU NOON EST – Team Meeting
May 6 FRI
May 9 Mon
May 10 Tue
May 11 WED NOON EST – Team Meeting
Dr. Williams unavailable from 10 AM to 8 PM attending and covering Mid Atlantic Robotics Group Meeting on 3D Bioprinting
May 12 THU NOON EST – Team Meeting
May 13 FRI
May 16 Mon
May 17 Tue
May 18 WED 10AM EST – Team Meeting – Presentations for 5/25
May 19 THU 10AM EST – Team Meeting – Presentations for 5/25
May 20 FRI
May 23 Mon
May 24 Tue
May 25 WED Postponed to 6/9 10AM EST – NOON EST – Team Meeting with Dr. George –
May 26 THU 10AM EST – Team Meeting discussion on 5/25 meeting
May 27 FRI
May 30 Mon MEMORIAL DAY
May 31 Tue
JUNE 2016
June 1 WED postponed to 6/16 10AM EST – Team Meeting with Dr. Nir –
June 2 THU – Aviva at 10th US-India BioPharma & Healthcare Summit, Thursday, June 2, 2016, Marriott Cambridge, MA
NO — 10AM EST – Team Meeting – discussion on 6/1 meeting
June 3 FRI
June 6 Mon
June 7 Tue
June 8 WED 10AM EST – Team Meeting
June 9 THU 10AM EST – Team Meeting – Presentation to Dr. George
June 10 FRI 9AM EST – Team Meeting – Presentation to Dr. Nir
ACTION POINTS from 6/9 and 6/10 Presentations:
1. Several Presentation Versions (PV) from the Master 77 Slides (Marter77):
PV 1: Non confidential for ROCHE
PV2: LPBI Group IP Position: Part I and Part II
PV3: LPBI Group’s Requirement to Use Akshaya Bio, Inc. Technology
PV4: LPBI Group’s Requirement to Use SBH Diagnostics, Inc.
PV5: Master77 converted into THREE SBIRs
PV1 to PV5 to be stored in DropBox — so each of us can edit
2. Schedule in July Skype Meeting on: Discussion among LPBI Group, Akshaya and SBH
3. Schedule in July Skype Meeting on: LPBI Group internal discussion on
- IP Structure,
- Organization Structure
4. FUNDING – Not for Profit, PDAC Foundation and Private Equity
June 13 MON
June 14 TUE
June 15 WED 10AM EST – No Team Meeting
June 16 THU 10AM EST – No Team Meeting
June 17 FRI
June 20 Mon
June 21 Tue – Aviva in Edmonton, AB, Canada
June 22 WED —>>>> NO Team Meeting – Aviva in Edmonton, AB, Canada
June 23 THU —>>>> NO Team Meeting – Aviva MEETS Dr. George in Edmonton, AB, Canada
June 24 FRI – Aviva in Banff, AB, Canada
June 27 Mon – Aviva in Banff, AB, Canada
June 28 Tue – Aviva back in Boston
June 29 WED 10AM EST – Team Meeting
June 30 THU 10AM EST – Team Meeting
July 1 FRI
JULY 2016
July 1, 2016 — Schedule of Skype Sessions – One-on-One with Aviva on Friday, July 1, 2016, 8AM EST to 6PM EST
0. Dr. Marc Feldman – 11AM EST
1. Dr. George – Noon EST
2. Dr. Jie Han – 1PM EST
3. Dr. Orchard-Webb – 2PM EST
4. Gail Thornton, PhD (c) – 3PM EST
5. Dr. Robu – 4PM EST
July 4 MON – HOLIDAY
6. Kelly Perlman – Monday at 10AM EST – Schedule of Skype Sessions – One-on-One with Aviva
July 5 TUE
July 6 WED – 9AM EST to 11AM EST – Team Internal discussions
July 7 THU – 10AM EST Team Meeting – Akshaya Bio Inc. and SBH Sciences, Inc. – Team meeting with Dr. Nir, Dr. George, Prof. Feldman Subject: Creation of a new entity in Drug Discovery
July 8 FRI
July 11 Mon
July 12 TUE
July 13 WED – Team Meeting
July 14 THU – 10AM EST follow up meeting with All participants of July
7, 2016
July 15 FRI
July 18 Mon
July 19 TUE
July 20 WED
July 21 THU – Team meeting at 10AM EST
July 22 FRI
July 25 Mon
July 26 TUE
July 27 WED – Team Meeting
July 28 THU – Team Meeting – GUEST Speakers
July 29 FRI
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22